Methods of using APOL1 inhibitors

APOL1 inhibitors provide a targeted treatment for diabetic retinopathies by addressing the cytotoxic effects of APOL1 variants and inflammation, offering a therapeutic option to manage and prevent vision-threatening conditions like diabetic macular edema and proliferative diabetic retinopathy.

WO2024249252A1PCT designated stage expired Publication Date: 2024-12-05MAZE THERAPEUTICS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/030759
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-05-23
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current treatments lack targeted therapies for diabetic retinopathies, specifically diabetic macular edema and proliferative diabetic retinopathy, which are associated with APOL1 variants and inflammation, leading to vision loss and blindness.

Method used

Administration of APOL1 inhibitors, potentially combined with anti-VEGF agents, Angiopoietin 2 blocking agents, corticosteroids, or laser therapy, to target the inflammatory pathways and cytotoxic effects of APOL1 variants in the eye.

Benefits of technology

The use of APOL1 inhibitors offers a therapeutic approach to treat and prevent diabetic retinopathies by mitigating the cytotoxic effects of APOL1 variants, potentially delaying disease progression and reducing inflammation in the eye.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024030759_05122024_PF_FP_ABST
    Figure US2024030759_05122024_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are methods of treating diabetic retinopathy in a subject, comprising administering to the subject a compound of Formula (A) or Formula (B): (A), (B) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, X3, X4, Z1, Z2, Z3, Z4, Ra, Rb, Rc, Rd, Re, L, Q, and Y are as defined herein.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No.: 79275-20026.40 METHODS OF USING APOL1 INHIBITORS CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application Serial No.63 / 469,335, filed May 26, 2023, which is hereby incorporated herein by reference in its entirety. BACKGROUND OF THE INVENTION

[0002] Diabetic retinopathy (DR) is a common complication of diabetes and a frequent cause of blindness in this population. Approximately 35% of diabetic patients have some form of retinopathy, which is characterized by retinal microaneurysms, occlusions and neovascularization with attendant loss in visual acuity. Approximately 20% of patients with DR have macular edema (DME) which is a result of fluid leak from the capillary beds into the retina and is associated with more advanced eye disease, including severe vision loss or blindness (Yau, J.W. et al, Meta-Analysis for Eye Disease Study G: Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564). The pathophysiology of retinal microvascular disease in the context of diabetes is complex, but has been associated with higher levels of inflammation, and inflammatory cytokines in the eye (Mason, R.H. et al, Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis. Eye 2022 Jun 7, doi: https: / / doi.org / 10.1038 / s41433-022- 02127-x). A locus containing the gene for APOL1 has been reported as a risk factor for DME based on a genetic analysis that provided evidence that an APOL1 missense variant is associated with increased risk for DME (Stockwell, A.D. et al, Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema. PLoS Genetics 19(8) (2023): e1010609.

[0003] APOL1 is an innate immune effector whose main known function is to suppress infection by Trypanosoma brucei, the cause of Human African Trypanosomiasis (Vanhamme, L. et al. Nature (2003) 422, 83-87). APOL1 is secreted from the liver as part of an HDL particle that is taken up by T. brucei where it forms a pore that results in lysis of the parasite (Rifkin, M. R. Proc. Natl. Acad. Sci. USA. (1978) 75, 3450-3454; Raper, J. et al. Infect. Immun. (1999) 67, 1910-1916). APOL1 is also expressed in other cell types throughout the body, including endothelial cells and podocytes, where it can be induced by various inflammatory cytokines 1ny-2734555Docket No.: 79275-20026.40 (Nystrom et al. JAK inhibitor blocks COVID-19 cytokine-induced JAK / STAT / APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids. JCI Insight.2022 Jun 8;7(11): e157432). APOL1 expressed in cell types outside of liver is thought to be largely intracellular (Cheng et al, J Lipid Res.2015 Aug;56(8):1583-93. doi: 10.1194 / jlr.M059733; Shukha et al, J Am Soc Nephrol.2017 Apr; 28(4): 1079–1083).

[0004] Missense variants G1 (S342G, I384M) and G2 (N388∆, Y389∆) in APOL1 that provide enhanced protection to T. brucei substrains have been associated with an increased risk of specific forms of kidney disease including, e.g., chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN) (Genovese, G. et al. Science. (2010) 329, 841-845; Tzur, S. et al. Hum. Genet. (2010) 128, 345-350; Kopp, J. B. et al. J. Am. Soc. Nephrol. (2011) 22, 2129-2137), sickle cell nephropathy (Ashley-Koch, A. E. et al. Br. J. Haematol. (2011) 155, 386-394), lupus nephritis (Freedman, B. I. et al. Arthritis Rheumatol. (2014) 66, 390-396), and an increased rate of Glomerular Filtration Rate (GFR) decline in diabetic kidney disease (Parsa, A. et al. N. Engl. J. Med. (2013) 369, 2183-2196). The APOL1 high-risk genotype has also been associated with COVID-19 associated nephropathy and other viral nephropathies (Shetty, A. et al. J. Am. Soc. Nephrol. (2021) 32, 33-40; Chang, J. H. et al. Am. J. Kidney Dis. (2019) 73, 134-139). These variants are predominantly found in individuals of West African descent and partially explain the substantially increased risk of end-stage kidney disease in this population (Genovese, G. et al. Science. (2010) 329, 841-845; Tzur, S. et al. Hum. Genet. (2010) 128, 345-350). These data provided the first evidence that dysregulation of APOL1 activity may cause disease. APOL1 induced kidney disease is thought to be due to pathological effects of intracellular APOL1, likely converging on APOL1 pore formation inside the cell.

[0005] There are currently no APOL1-targeted therapies for treating eye diseases such as DR and DME. There remains a need for therapies to treat these conditions. BRIEF SUMMARY OF THE INVENTION

[0006] This disclosure describes methods for treating diabetic retinopathies including non- proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema comprising administration of an APOL1 inhibitor orny-2734555Docket No.: 79275-20026.40 composition comprising an APOL1 inhibitor. Additionally, the disclosed methods may prevent the onset of diabetic retinopathies and / or delay the progression of diabetic retinopathies. The APOL1 inhibitor may be administered as a single agent or in combination with other agents including, e.g., anti-VEGF agents, Angiopoietin 2 blocking agents, dual VEGF-Angiopoietin 2 blocking agents, corticosteroids, and / or laser therapy.

[0007] A genetic link between a missense variant in APOL1 and DME has been established (Stockwell, A.D. et al, Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema. PLoS Genetics 19(8) (2023): e1010609; herein incorporated by reference in its entirety). This variant contains glutamic acid instead of lysine at position 150 (E150 APOL1). E150 APOL1 has been shown to enhance the cytotoxic effects of APOL1 when overexpressed (Lannon et al, Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background. Kidney International (2019) 96, 1303–1307; herein incorporated by reference in its entirety) and may explain the association of this APOL1 variant with diseases of the eye. APOL1 has been shown to be expressed in various cell types in the eye including endothelial cells and fibroblasts (Gautam et al. Multi-species single-cell transcriptomic analysis of ocular compartment regulons. Nat Commun.2021 Sep 28;12(1):5675; herein incorporated by reference in its entirety).

[0008] DME and DR are associated with higher levels of inflammation, and inflammatory cytokines in the eye (Mason, R.H. et al, Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis. Eye 2022 Jun 7, doi: https: / / doi.org / 10.1038 / s41433-022-02127-x; herein incorporated by reference in its entirety). Inflammatory cytokines like interferons, IL-1β and TNF-α are known inducers of APOL1 in endothelial cells (Nichols et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int.2015 Feb;87(2):332-42; Nystrom et al. JAK inhibitor blocks COVID-19 cytokine-induced JAK / STAT / APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids. JCI Insight.2022 Jun 8;7(11):e157432; each herein incorporated by reference in its entirety). Interferon therapy can lead to retinopathy and macular edema, through mechanisms that remain unclear (Tokai et al. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol.2001 Jul;119(7):1077-9; Zubir et al. Interferon-α-ny-2734555Docket No.: 79275-20026.40 induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol.2019 Mar;257(3):447-452; each herein incorporated by reference in its entirety). Since interferon is a potent inducer of APOL1, it is plausible that these ocular effects could be driven through interferon mediated induction of APOL1 in eye tissues. In support of this concept, endothelial specific APOL1 expression has been reported to cause vascular leak in mouse models, consistent with the vascular leak seen in DR and DME (Wu et al, APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis. Immunity.2021 Nov 9; 54(11): 2632–2649.e6; herein incorporated by reference in its entirety).

[0009] A cytotoxic APOL1 variant (E150 APOL1) is genetically associated with diabetic eye disease, and the overexpression of this variant drives toxicity in cellular models. APOL1 is expressed in the eye in cell types known to be relevant to the pathophysiology of diabetic eye disease including endothelial cells. Therapeutic use of interferon, which induces APOL1 expression in endothelial cells, is also associated with ocular side effects including retinopathy and macular edema. APOL1 induction in mouse models results in vascular leak, consistent with the role of vascular leak in diabetic eye diseases. APOL1 pore blockers have been shown to protect cells from cytotoxicity associated with kidney disease associated variants. Therefore, APOL1 inhibitors as disclosed herein may be therapeutically beneficial in patients with or at risk of developing DME or DR. Moreover, the APOL1 inhibitors as disclosed herein may be administered by a variety of routes including, e.g., oral administration.

[0010] In one aspect, provided herein is a method of treating diabetic retinopathy in a subject in need thereof, comprising administering to the subject a compound of Formula (A) or Formula (B):or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: 4ny-2734555Docket No.: 79275-20026.40 when the compound is a compound of formula A, Q is absent or is -N-(C1-6alkyl); Y is O or -N-(C1-6alkyl), provided that, when Q is -N(C1-6alkyl), then Y is O; Ra, Rb, and Rcare each independently H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl, or any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl; L is selected from the group consisting of: (i), wherein A is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rxis H, or Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0- 6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy; R1and R2are independently H, halo, or -OH, or one of R1and R2is taken together with Rx, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl isny-2734555Docket No.: 79275-20026.40 substituted with n independently selected Rgsubstituents, wherein n is an integer from 0- 6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, and the other of R1and R2is H, halo, or - OH; R3is H, -OH, halo, or C1-6alkoxy; and R4and R5are independently H, or R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl, provided that either: (1) Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C1-6alkyl, or C1-6alkoxy, or (2) R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl; (ii), wherein E is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); p is 0 or 1, provided that, when p is 1, then E is O; R6is H or -OH; Ryis H, 6ny-2734555Docket No.: 79275-20026.40 or Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R7is H, or R7is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R8and R9are independently H or C1-6alkyl, or one of R8and R9is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R8and R9is H or C1-6alkyl, or one of R8and R9is taken together with R10, and the atoms to which they are attached, to form a C3-8cycloalkyl, and the other of R8and R9is H or C1-6alkyl; and R10is H, or R10is taken together with one of R8and R9, and the atoms to which they are attached, to form a C3-8cycloalkyl, provided that: (1) Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (2) Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (3) one of R8and R9is taken together with R10and the atoms to which they are attached, to form a C3-8cycloalkyl; andny-2734555Docket No.: 79275-20026.40 G is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rzis H or C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more C3-8cycloalkyl; R11and R12are independently H, -OH, halo, or C1-6alkyl; and R13and R14are independently H, C1-6alkyl, or C3-8cycloalkyl, or R13and R14are taken, together with the atoms to which they are attached, to form a 3- 8 membered heterocyclyl, wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4; and X1, X2, X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, provided that at least one of X1, X2, X3, and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and when the compound is a compound of Formula (B), m is 0 or 1; Y is O or -N(C1-6alkyl), wherein the C1-6alkyl is optionally substituted with one or more Rgsubstituents; Z1, Z2, Z3, and Z4are, independently of each other, -N-, -CH- or -C(Rf)-; Ra, Rb, and Rcare each independently H, C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, andny-2734555Docket No.: 79275-20026.40 the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents, or any two of Ra, Rb, and Rcare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is optionally substituted with one or more Risubstituents, and the other of Ra, Rb, and Rcis H or C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents; Rdand Reare each independently H or C1-6alkyl, or Rdand Reare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-6 membered heterocycle; Rfis, independently at each occurrence, -CN, halo, C1-6alkyl, C1-6alkoxy, or -N(Rj)2, wherein the C1-6alkyl of Rfis optionally substituted with one or more halo; Rgis, independently at each occurrence, -S(O)2C1-6alkyl; Rhis, independently at each occurrence, -OH, C1-6alkoxy, -N(Rj)2, C(O)Rk, or -S(O)2C1-6alkyl; Riis, independently at each occurrence, oxo, C1-6alkyl, or C(O)Rk; Rjis independently at each occurrence H, C1-6alkyl or C(O)C1-6alkyl; Rkis, independently at each occurrence C1-6alkyl or C1-6alkoxy; L is selected from the group consisting of:ny-2734555Docket No.: 79275-20026.40, wherein Rxand R1are taken together with the atoms to which they are attached to form a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; R2is H, -OH, or C1-6alkyl, wherein the C1-6alkyl of R2is optionally substituted with one or more OH; and R3is H or C1-6alkyl, wherein the C1-6alkyl of R3is optionally substituted with one or more OH; provided that when L is (i), either: (1) m is 1, (2) at least one of Z1, Z2, Z3, and Z4is -N- or -C(Rf)-, (3) R3is other than H, (4) at least one of Ra, Rb, and Rcis heterocycle, or (5) at least one of Rg, Ri, Rj, Rk, and Rnis present;, wherein Ry, R4, and R5are taken together with the atoms to which they are attached to form a 8-20 membered bicyclic heterocycle, wherein the 8-20 membered bicyclic heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-10ny-2734555Docket No.: 79275-20026.406alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; or, wherein Rzand R6are taken together with the atoms to which they are attached to form a 3-8 membered heterocycleheterocycle substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; and R7is taken, together with one of X1and X2and the atoms to which they are attached, to form a C4-8cycloalkyl; wherein, for each of (i)-(iii), # denotes the point of attachment to the ring bearing moieties moieties Z1-Z4and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4; X1, and X2are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, or one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, and the other of X1or X2is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.

[0011] In one aspect, provided herein is a method of preventing and / or delaying the development of diabetic retinopathy in a subject in need thereof, comprising administering to the subject a compound of Formula (A) or Formula (B). In one aspect, provided herein is a method of 11ny-2734555Docket No.: 79275-20026.40 delaying the development of diabetic retinopathy in a subject in need thereof, comprising administering to the subject a compound of Formula (A) or Formula (B).

[0012] Articles of manufacture are also provided, wherein the article of manufacture comprises a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in a suitable container. Also provided herein are articles of manufacture, comprising a pharmaceutical composition comprising a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, or intravenous bag. BRIEF DESCRIPTION OF THE FIGURES

[0013] FIG.1 shows compounds A-1 to A-215 as disclosed herein.

[0014] FIG.2 shows compounds B-1 to B-145 as disclosed herein.

[0015] FIG.3 shows the results of an APOL1 E150 G2 mouse transgenic model to validate acute effects of interferon on APOL1 expression in eye retinal tissue.

[0016] FIG.4 shows the results of an APOL1 E150 G2 mouse transgenic model to validate chronic effects of interferon on APOL1 expression in eye tissue. DETAILED DESCRIPTION OF THE INVENTION

[0017] Unless clearly indicated otherwise, the terms “a,” “an,” and the like, refer to one or more.

[0018] As used herein, “about” a parameter or value includes and describes that parameter or value per se. For example, “about X” includes and describes X per se.

[0019] “Individual” refers to mammals and includes humans and non-human mammals. Examples of individuals include, but are not limited to, some primates and humans. In some embodiments, individual refers to a human.

[0020] As used herein, an “at risk” individual is an individual who is at risk of developing a disease or condition. An individual “at risk” may or may not have a detectable disease or 12ny-2734555Docket No.: 79275-20026.40 condition, and may or may not have displayed detectable disease prior to the treatment methods described herein. “At risk” denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual having one or more of these risk factors has a higher probability of developing the disease or condition than an individual without these risk factor(s).

[0021] “Treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired results may include one or more of the following: decreasing one or more symptom resulting from the disease or condition; diminishing the extent of the disease or condition; slowing or arresting the development of one or more symptom associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition); and relieving the disease, such as by causing the regression of clinical symptoms (e.g., ameliorating the disease state, enhancing the effect of another medication, delaying the progression of the disease, increasing the quality of life, and / or prolonging survival).

[0022] As used herein, “delaying” development of a disease or condition means to defer, hinder, slow, retard, stabilize and / or postpone development of the disease or condition. This delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease or condition.

[0023] As used herein, the term “therapeutically effective amount” or “effective amount” intends such amount of a compound of the disclosure or a pharmaceutically salt thereof sufficient to effect treatment when administered to an individual. As is understood in the art, an effective amount may be in one or more doses, e.g., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved.

[0024] As used herein, “unit dosage form” refers to physically discrete units, suitable as unit dosages, each unit containing a predetermined quantity of active ingredient, or compound, which may be in a pharmaceutically acceptable carrier. 13ny-2734555Docket No.: 79275-20026.40

[0025] As used herein, by “pharmaceutically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects.

[0026] The term “alkyl”, as used herein, refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1-20 carbons (i.e., C1-20alkyl), 1-16 carbons (i.e., C1-16alkyl), 1-12 carbons (i.e., C1-12alkyl), 1-10 carbons (i.e., C1-10alkyl), 1-8 carbons (i.e., C1-8alkyl), 1-6 carbons (i.e., C1-6alkyl), 1-4 carbons (i.e., C1-4alkyl), or 1-3 carbons (i.e., C1-3alkyl). Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, iso-propyl, n- butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, iso-pentyl, neo-pentyl, hexyl, 2-hexyl, 3- hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or molecular formula, all positional isomers having that number of carbon atoms may be encompassed—for example, “butyl” includes n-butyl, sec-butyl, iso-butyl, and tert-butyl; and “propyl” includes n-propyl and iso-propyl. Certain commonly used alternative names may be used and will be understood by those of ordinary skill in the art. For instance, a divalent group, such as a divalent “alkyl” group, may be referred to as an “alkylene”.

[0027] The term “alkoxy”, as used herein, refers to an -O-alkyl moiety. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert- butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0028] The term “aryl”, as used herein, refers to a fully unsaturated carbocyclic ring moiety. The term “aryl” encompasses monocyclic and polycyclic fused-ring moieties. As used herein, aryl encompasses ring moieties comprising, for example, 6 to 20 annular carbon atoms (i.e., C6-20aryl), 6 to 16 annular carbon atoms (i.e., C6-16aryl), 6 to 12 annular carbon atoms (i.e., C6-12aryl), or 6 to 10 annular carbon atoms (i.e., C6-10aryl). Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, fluorenyl, and anthryl.

[0029] The term “cycloalkyl”, as used herein, refers to a saturated or partially unsaturated carbocyclic ring moiety. The term “cycloalkyl” encompasses monocyclic and polycyclic ring moieties, wherein the polycyclic moieties may be fused, branched, or spiro. Cycloalkyl includes cycloalkenyl groups, wherein the ring moiety comprises at least one annular double bond. Cycloalkyl includes any polycyclic carbocyclic ring moiety comprising at least one non-aromatic ring, regardless of the point of attachment to the remainder of the molecule. As used herein, 14ny-2734555Docket No.: 79275-20026.40 cycloalkyl includes rings comprising, for example, 3 to 20 annular carbon atoms (i.e., a C3-20cycloalkyl), 3 to 16 annular carbon atoms (i.e., a C3-16cycloalkyl), 3 to 12 annular carbon atoms (i.e., a C3-12cycloalkyl), 3 to 10 annular carbon atoms (i.e., a C3-10cycloalkyl), 3 to 8 annular carbon atoms (i.e., a C3-8cycloalkyl), 3 to 6 annular carbon atoms (i.e., a C3-6cycloalkyl), or 3 to 5 annular carbon atoms (i.e., a C3-5cycloalkyl). Monocyclic cycloalkyl ring moieties include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbomyl, decalinyl, 7,7-dimethyl -bicyclo [2.2.1]heptanyl, and the like. Still further, cycloalkyl also includes spiro cycloalkyl ring moieties, for example, spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro [5.5]undecanyl.

[0030] The term “halo”, as used herein, refers to atoms occupying groups VIIA of The Periodic Table and includes fluorine (fluoro), chlorine (chloro), bromine (bromo), and iodine (iodo).

[0031] The term “heteroaryl”, as used herein, refers to an aromatic (fully unsaturated) ring moiety that comprises one or more annular heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term “heteroaryl” includes both monocyclic and polycyclic fused-ring moieties. As used herein, a heteroaryl comprises, for example, 5 to 20 annular atoms (i.e., a 5-20 membered heteroaryl), 5 to 16 annular atoms (i.e., a 5-16 membered heteroaryl), 5 to 12 annular atoms (i.e., a 5-12 membered heteroaryl), 5 to 10 annular atoms (i.e., a 5-10 membered heteroaryl), 5 to 8 annular atoms (i.e., a 5-8 membered heteroaryl), or 5 to 6 annular atoms (i.e., a 5-6 membered heteroaryl). Any monocyclic or polycyclic aromatic ring moiety comprising one or more annular heteroatoms is considered a heteroaryl, regardless of the point of attachment to the remainder of the molecule (i.e., the heteroaryl moiety may be attached to the remainder of the molecule through any annular carbon or any annular heteroatom of the heteroaryl moiety). Examples of heteroaryl groups include, but are not limited to, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl,ny-2734555Docket No.: 79275-20026.40 isoquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, and triazinyl. Examples of the fused- heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolinyl, isoquinolinyl, benzo[b]thiophenyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5- a]pyridinyl, wherein the heteroaryl can be bound via either ring of the fused system.

[0032] The term “heterocyclyl”, as used herein, refers to a saturated or partially unsaturated cyclic moiety that encompasses one or more annular heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term “heterocyclyl” includes both monocyclic and polycyclic ring moieties, wherein the polycyclic ring moieties may be fused, bridged, or spiro. Any non-aromatic monocyclic or polycyclic ring moiety comprising at least one annular heteroatom is considered a heterocyclyl, regardless of the point of attachment to the remainder of the molecule (i.e., the heterocyclyl moiety may be attached to the remainder of the molecule through any annular carbon or any annular heteroatom of the heterocyclyl moiety). Further, the term heterocyclyl is intended to encompass any polycyclic ring moiety comprising at least one annular heteroatom wherein the polycyclic ring moiety comprises at least one non- aromatic ring, regardless of the point of attachment to the remainder of the molecule. As used herein, a heterocyclyl comprises, for example, 3 to 20 annular atoms (i.e., a 3-20 membered heterocyclyl), 3 to 16 annular atoms (i.e., a 3-16 membered heterocyclyl), 3 to 12 annular atoms (i.e., a 3-12 membered heterocyclyl), 3 to 10 annular atoms (i.e., a 3-10 membered heterocyclyl), 3 to 8 annular atoms (i.e., a 3-8 membered heterocyclyl), 3 to 6 annular atoms (i.e., a 3-6 membered heterocyclyl), 3 to 5 annular atoms (i.e., a 3-5 membered heterocyclyl), 5 to 8 annular atoms (i.e., a 5-8 membered heterocyclyl), or 5 to 6 annular atoms (i.e., a 5-6 membered heterocyclyl). Examples of heterocyclyl groups include, e.g., azetidinyl, azepinyl, benzodioxolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiophenyl (i.e., thienyl), thiomorpholinyl, thiamorpholinyl, 1- oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Examples of spiro heterocyclyl rings 16ny-2734555Docket No.: 79275-20026.40 include, but are not limited to, bicyclic and tricyclic ring systems, such as oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6- oxa-1-azaspiro[3.3]heptanyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system.

[0033] The terms “optional” and “optionally”, as used herein, mean that the subsequently described event or circumstance may or may not occur and that the description includes instances where the event or circumstance occurs and instances where it does not. Accordingly, the term “optionally substituted” infers that any one or more (e.g., 1, 2, 1 to 5, 1 to 3, 1 to 2, etc.) hydrogen atoms on the designated atom or moiety or group may be replaced or not replaced by an atom or moiety or group other than hydrogen. By way of illustration and not limitation, the phrase “methyl optionally substituted with one or more chloro” encompasses -CH3, -CH2Cl, - CHCl2, and -CCl3moieties.

[0034] It is understood that aspects and embodiments described herein as “comprising” include “consisting of” and “consisting essentially of ” embodiments.

[0035] The term “pharmaceutically acceptable salt”, as used herein, of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” include, for example, salts with inorganic acids, and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. See, e.g., Handbook of Pharmaceutical Salts Properties, Selection, and Use, International Union of Pure and Applied Chemistry, John Wiley & Sons (2008), which is incorporated herein by reference. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolicny-2734555Docket No.: 79275-20026.40 acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, trifluoroacetic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2- dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0036] Isotopically labeled forms of the compounds depicted herein may be prepared. Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as2H,3H,11C,13C,14C,13N,15N,15O,17O,18O,31P,32P,35S,18F,36Cl,123I, and125I, respectively. In some embodiments, a compound of formula (A), or formula (B), or variation thereof, is provided wherein one or more hydrogen is replaced by deuterium or tritium.

[0037] In some embodiments, compounds described herein contain one or more hydrogen atoms that are replaced with deuterium, wherein deuterium is present in an amount that is greater than its natural abundance. Thus, as used herein, designation of an atom as deuterium at a position indicates that the abundance of deuterium is significantly greater than the natural abundance of deuterium. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen,” the position is understood to have hydrogen at its naturally abundant isotopic composition. Also unless otherwise stated, when a position is designated specifically as “D” or “deuterium,” the position is understood to have deuterium at an abundance that is significantly greater than the natural abundance of deuterium, e.g., at least 3000 times greater than the natural abundance of deuterium, which is about 0.015% (i.e., the term “D” or “deuterium” indicates at least about 45% incorporation of deuterium).

[0038] Some of the compounds provided herein may exist as tautomers. Tautomers are in equilibrium with one another. By way of illustration, amide containing compounds may exist in 18ny-2734555Docket No.: 79275-20026.40 equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds of this disclosure are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, for example, amide-containing compounds are understood to include their imidic acid tautomers. Likewise, imidic-acid containing compounds are understood to include their amide tautomers.

[0039] Also provided herein are prodrugs of the compounds depicted herein, or a pharmaceutically acceptable salt thereof. Prodrugs are compounds that may be administered to an individual and release, in vivo, a compound depicted herein as the parent drug compound. It is understood that prodrugs may be prepared by modifying a functional group on a parent drug compound in such a way that the modification is cleaved in vivo to release the parent drug compound. See, e.g., Rautio, J., Kumpulainen, H., Heimbach, T. et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7, 255–270 (2008), which is incorporated herein by reference in its entirety.

[0040] The compounds of the present disclosure, or their pharmaceutically acceptable salts, may include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- (or as (D)- or (L)- for amino acids). The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms and mixtures thereof in any ratio. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or may be resolved using conventional techniques, for example, chromatography and / or fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or the resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC), and chiral SFC (supercritical fluid chromatography). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless specified otherwise, it is intended that the present disclosure includes both E and Z geometric isomers. Likewise, cis- and trans- are used in their conventional sense to describe relative spatial relationships.

[0041] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds, but having different three-dimensional structures, which are not interchangeable. The 19ny-2734555Docket No.: 79275-20026.40 present disclosure contemplates various stereoisomers, or mixtures thereof, and includes “enantiomers,” which refers to two stereoisomers whose structures are non-superimposable mirror images of one another. “Diastereomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other.

[0042] Where enantiomeric and / or diastereomeric forms exist of a given structure, flat bonds indicate that all stereoisomeric forms of the depicted structure may be present, e.g.,.

[0043] Where enantiomeric forms exist of a given structure, flat bonds and the presence of a “ * ” symbol indicate that the composition is made up of at least 90%, by weight, of a single isomer with unknown stereochemistry,example, with reference to the figures, in FIG.1, Compound A2 may represent (R)-1-(3-chlorophenethyl)-3-((4- (methylsulfonyl)phenoxy)methyl)azepane, and Compound A3 may represent (S)-1-(3- chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane. Altenatively, Compound A2 may represent (S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane, and Compound A3 may represent (R)-1-(3-chlorophenethyl)-3-((4- (methylsulfonyl)phenoxy)methyl)azepane. In some variations the asterisk denotes a stereocenter having an (R) configuration. In other variations the asterisk denotes a stereocenter having an (S) configuration.

[0044] Where enantiomeric and / or diastereomeric forms exist of a given structure, wedged or hashed bonds indicate the composition is made up of at least 90%, by weight, of a single enantiomer or diastereomer with known stereochemistry, e.g.,. 20ny-2734555Docket No.: 79275-20026.40

[0045] Where enantiomeric and / or diastereomeric forms exist of a given structure with two stereocenters, flat bonds and the presence of two “&1” symbols indicate the composition is made up of a pair of enantiomers with unknown relative stereochemistry, e.g.,.

[0046] Where enantiomeric and / or diastereomeric forms exist of a given structure with two stereocenters, wedged and / or dashed bonds and the presence of two “&1” symbols indicate the composition is made up of a pair of enantiomers with known relative stereochemistry, e.g.,.

[0047] Where enantiomeric and / or diastereomeric forms exist of a given structure with two stereocenters, wedged and / or dashed bonds and the presence of two “or1” symbols indicate the composition is made up of at least 90%, by weight, a single stereoisomer with known relative stereochemistry but unknown absolute stereochemistry, e.g.,.

[0048] Where enantiomeric and / or diastereomeric forms exist of a given structure with two stereocenters, flat bonds and the presence of two “ * ” symbols indicate the composition is made up of at least 90%, by weight, of a single enantiomer or diastereomer with unknown stereochemistry, e.g.,. 21ny-2734555Docket No.: 79275-20026.40

[0049] Abbreviations used are those conventional in the art and are in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. The following examples are intended to be illustrative only and not limiting in any way. °C degrees Celsius LiHMDS lithium bis(trimethylsilyl)amide μL microliter mCPBA or meta-chloroperoxybenzoic acid m-CPBA [M+XX]+observed mass MeOH methanol AC50half-maximal activity MeCN acetonitrile concentration AcOH acetic acid m multiplet (NMR) AIBN azobisisobutyronitrile mg milligrams app apparent (NMR) min minutes b broad (as in “br s” to mL milliliter indicate a broad singlet) BH3·THF borane-tetrahydrofuran mmol millimole complex BBr3boron tribromide mM millimolar Calc’d calculated M molarity or molar Cbz-Cl or benzyl chloroformate MS mass spectrometry CbzCl CO2carbon dioxide MsCl methanesulfonyl chloride Cs2CO3cesium carbonate MTBE methyl tert-butyl ether d deuterated (NMR solvents) n / a not applicable d doublet (NMR) NH4ammonium dd doublet of doublets (NMR) NH4OH ammonium hydroxide DCE 1,2-dichloroethane NH4HCO3ammonium bicarbonate DCM dichloromethane Na2SO4sodium sulfate DIAD diisopropyl NaBH3CN sodium cyanoborohydride azodicarboxylate DMF N,N-dimethylformamide NMR nuclear magnetic resonance DMP Dess–Martin periodinane NaOH sodium hydroxide EC50half-maximal effective Pd(dppf)Cl2[1,1′- concentration bis(diphenylphosphino)ferrocene ]dichloropalladium(II) EtOAc ethyl acetate Pd / C palladium on carbon EtOH ethanol pH potential of hydrogen g grams PPh3 triphenyl phosphine h hours s singlet (NMR) H hydrogen SFC supercritical fluid chromatography HCl hydrochloric acid t triplet (NMR) HPLC high-performance liquid TBAB tetrabutylammonium bromide chromatography In vacuo in a vacuum TEA triethylamine 22ny-2734555Docket No.: 79275-20026.40 IUPAC International Union of Pure TFA trifluoroacetic acid and Applied Chemistry MHz megahertz THF tetrahydrofuran J J-coupling value (NMR) TMAD tetramethylazodicarboxamide K2CO3potassium carbonate TMSCl trimethylsilyl chloride METHODS OF TREATMENT

[0050] In one aspect, provided herein is a method of treating diabetic retinopathy in a subject in need thereof, comprising administering to the subject an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, the diabetic retinopathy is selected from the group consisting of non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema. In some embodiments, a therapeutically effective amount of the APOL1 inhibitor or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient is administered. In some embodiments, the administration comprises oral administration or intravitreal injection. In some embodiments, the administration comprises oral administration. In some ebodiments, the administration comprises intravitreal injection. In some embodiments, the method further comprises administration of an anti-VEGF agent, an Angiopoietin 2 blocking agent, a dual VEGF-Angiopoietin 2 blocking agent, a corticosteroid, or laser therapy to the subject.

[0051] In one aspect, provided herein is a method of treating or alleviating diabetic retinopathy in a subject, comprising administering to the subject a compound of formula (A) or formula (B):or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: when the compound is a compound of formula A, 23ny-2734555Docket No.: 79275-20026.40 Q is absent or is -N-(C1-6alkyl); Y is O or -N-(C1-6alkyl), provided that, when Q is -N(C1-6alkyl), then Y is O; Ra, Rb, and Rcare each independently H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2- C1-6alkyl, or any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl; L is selected from the group consisting of: (i), wherein A is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rxis H, or Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy; R1and R2are independently H, halo, or -OH, or one of R1and R2is taken together with Rx, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein 24ny-2734555Docket No.: 79275-20026.40 n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, and the other of R1and R2is H, halo, or -OH; R3is H, -OH, halo, or C1-6alkoxy; and R4and R5are independently H, or R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl, provided that either: (1) Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C1-6alkyl, or C1-6alkoxy, or (2) R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl,, wherein E is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); p is 0 or 1, provided that, when p is 1, then E is O; R6is H or -OH; Ryis H, or Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl,ny-2734555Docket No.: 79275-20026.40 or Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R7is H, or R7is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R8and R9are independently H or C1-6alkyl, or one of R8and R9is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R8and R9is H or C1-6alkyl, or one of R8and R9is taken together with R10, and the atoms to which they are attached, to form a C3-8cycloalkyl, and the other of R8and R9is H or C1-6alkyl; and R10is H, or R10is taken together with one of R8and R9, and the atoms to which they are attached, to form a C3-8cycloalkyl, provided that: (1) Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (2) Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (3) one of R8and R9is taken together with R10and the atoms to which they are attached, to form a C3-8cycloalkyl, and (iii)26ny-2734555Docket No.: 79275-20026.40 G is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rzis H or C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more C3-8cycloalkyl; R11and R12are independently H, -OH, halo, or C1-6alkyl; and R13and R14are independently H, C1-6alkyl, or C3-8cycloalkyl, or R13and R14are taken, together with the atoms to which they are attached, to form a 3- 8 membered heterocyclyl, wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4; and X1, X2, X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, provided that at least one of X1, X2, X3, and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; when the compound is a compound of Formula (B), m is 0 or 1; Y is O or -N(C1-6alkyl), wherein the C1-6alkyl of the -N(C1-6alkyl) is optionally substituted with one or more Rgsubstituents; Z1, Z2, Z3, and Z4are, independently of each other, -N-, -CH- or -C(Rf)-; Ra, Rb, and Rcare each independently H, C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, andny-2734555Docket No.: 79275-20026.40 the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents, or any two of Ra, Rb, and Rcare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is optionally substituted with one or more Risubstituents, and the other of Ra, Rb, and Rcis H or C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents; Rdand Reare each independently H or C1-6alkyl, or Rdand Reare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-6 membered heterocycle; Rfis, independently at each occurrence, -CN, halo, C1-6alkyl, C1-6alkoxy, or -N(Rj)2, wherein the C1-6alkyl of Rfis optionally substituted with one or more halo; Rgis, independently at each occurrence, -S(O)2C1-6alkyl; Rhis, independently at each occurrence, -OH, C1-6alkoxy, -N(Rj)2, C(O)Rk, or -S(O)2C1-6alkyl; Riis, independently at each occurrence, oxo, C1-6alkyl, or C(O)Rk; Rjis independently at each occurrence H, C1-6alkyl or C(O)C1-6alkyl; Rkis, independently at each occurrence C1-6alkyl or C1-6alkoxy; L is selected from the group consisting of: 28ny-2734555Docket No.: 79275-20026.40 (i), wherein Rxand R1are taken together with the atoms to which they are attached to form a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; R2is H, -OH, or C1-6alkyl, wherein the C1-6alkyl of R2is optionally substituted with one or more OH; and R3is H or C1-6alkyl, wherein the C1-6alkyl of R3is optionally substituted with one or more OH; provided that when L is (i), either: (1) m is 1, (2) at least one of Z1, Z2, Z3, and Z4is -N- or -C(Rf)-, (3) R3is other than H, (4) at least one of Ra, Rb, and Rcis heterocycle, or (5) at least one of Rg, Ri, Rj, Rk, and Rnis present; (ii), wherein Ry, R4, and R5are taken together with the atoms to which they are attached to form a 8- 20 membered bicyclic heterocycle, wherein the 8-20 membered bicyclic heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0- 29ny-2734555Docket No.: 79275-20026.40 6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; or (iii), wherein Rzand R6are taken together with the atoms to which they are attached to form a 3-8 membered heterocycleheterocycle substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; and R7is taken, together with one of X1and X2and the atoms to which they are attached, to form a C4-8cycloalkyl; wherein, for each of (i)-(iii), # denotes the point of attachment to the ring bearing moieties moieties Z1-Z4and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4; X1, and X2are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, or one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, and the other of X1or X2is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments of the compound of formula (A), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of FIG.1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of the compound of formula (B), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically 30ny-2734555Docket No.: 79275-20026.40 acceptable salt of any of the foregoing, the compound is a compound of FIG.2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the diabetic retinopathy is selected from the group consisting of non- proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema. In some embodiments, the administration comprises oral administration or intravitreal injection. In some embodiments, the administration comprises oral administration. In some embodiments, the administration comprises intravitreal injection. In some embodiments, the method further comprises administration of an anti-VEGF agent, an Angiopoietin 2 blocking agent, a dual VEGF-Angiopoietin 2 blocking agent, a corticosteroid, or laser therapy to the subject.

[0052] In one aspect, provided herein is a method of preventing and / or delaying the development of diabetic retinopathy in a subject, comprising administering to the subject a compound of formula (A) or formula (B). In one aspect, provided herein is a method of delaying the development of diabetic retinopathy in a subject, comprising administering to the subject a compound of formula (A) or formula (B). In some embodiments of the compound of formula (A), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of FIG. 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of the compound of formula (B), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of FIG.2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the diabetic retinopathy is selected from the group consisting of non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema. In some embodiments, the administration comprises oral administration or intravitreal injection. In some embodiments, the administration comprises oral administration. In some embodiments, the administration comprises intravitreal injection. In some embodiments, the method further comprises administration of an anti-VEGF agent, an Angiopoietin 2 blocking agent, a dual VEGF-Angiopoietin 2 blocking agent, a corticosteroid, or laser therapy to the subject. 31ny-2734555Docket No.: 79275-20026.40

[0053] In some embodiments of the methods described herein, the method comprises administering to the subject a compound of formula (A) or formula (B) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In some embodiments, a therapeutically effective amount of the compound of formula (A) or formula (B) or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient is administered. In some embodiments of the compound of formula (A), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of FIG. 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments of the compound of formula (B), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of FIG.2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0054] In some embodiments of the compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L is, such that the compound of formula (A) is a compound of formula (A-I):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0055] In some embodiments of the compound of formula (A) or formula (A-I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, A is O, such that the compound is of formula (A-I-A1): 32ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0056] In some embodiments of the compound of formula (A) or formula (A-I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, A is NH, such that the compound is of formula (A-I-A2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, A is N(C1-6alkyl).

[0057] In some embodiments of the compound of formula (A) or formula (A-I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, A is CH2, such that the compound is of formula (A-I-A3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, A is CH(C1-6alkyl). In some embodiments, A is CH(CH3).

[0058] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), (A-I-A2), or (A-I-A3), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is 33ny-2734555Docket No.: 79275-20026.40 substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy. In some embodiments, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-6 membered heterocyclyl, wherein the 3-6 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy. In some embodiments, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 5-8 membered heterocyclyl, wherein the 5-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy. In some embodiments, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 5-6 membered heterocyclyl, wherein the 5-6 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy. Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 5- membered heterocyclyl, wherein the 5-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy. Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy.

[0059] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 5- membered heterocyclyl, wherein the 5-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-B1): 34ny-2734555Docket No.: 79275-20026.40

[0060] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A2), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 5- membered heterocyclyl, wherein the 5-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-B2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0061] In some embodiments of the a compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A3), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 5- membered heterocyclyl, wherein the 5-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-B3):ny-2734555Docket No.: 79275-20026.40

[0062] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-C1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0063] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A2), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-C2): 36 ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0064] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A3), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-C3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0065] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-D1):ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0066] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A2), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-D2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0067] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A3), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-D3): 38ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0068] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-E1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0069] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A2), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-E2): 39ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0070] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A3), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 6- membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-E3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0071] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-E1), (A-I-E2), or (A-I-E3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 0. In some embodiments, n is 1.

[0072] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 7- membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-F1): 40ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0073] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A2), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 7- membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-F2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0074] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A3), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 7- membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-F3): 41ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0075] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 7- membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-G1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0076] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A2), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 7- membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-G2): 42ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0077] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A3), or a pharmaceutically acceptable salt of any of the foregoing, Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 7- membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0-6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, wherein the compound is of formula (A-I-G3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0078] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A- I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), or (A-I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0-6. In some embodiments, n is an integer from 0-5. In some embodiments, n is an integer from 0-4. In some embodiments, n is an integer from 0-3. In some embodiments, n is an integer from 0-2. In some embodiments, n is 0 or 1. In some embodiments, n is an integer from 1-6. In some embodiments, n is an integer from 1-5. In some embodiments, n is an integer from 1-4. In some embodiments, 43ny-2734555Docket No.: 79275-20026.40 n is an integer from 1-3. In some embodiments, n is 1 or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

[0079] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A- I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), or (A-I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy. In some embodiments, Rgis -OH, C1-6alkyl, or C1-6alkoxy. In some embodiments, Rgis -OH, halo, C1-3alkyl, or C1-3alkoxy. In some embodiments, Rgis -OH, methyl, or methoxy. In some embodiments, Rgis -OH. In some embodiments, Rgis C1-6alkyl. In some embodiments, Rgis methyl. In some embodiments, Rgis C1-6alkoxy. In some embodiments, Rgis methoxy. In some embodiments, Rgis halo. In some embodiments, Rgis fluoro.

[0080] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A- I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), or (A-I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1 and Rgis C1-6alkyl. In some embodiments, n is 1 and Rgis methyl. In some embodiments, n is 2 and each Rgis C1-6alkyl. In some embodiments, n is 2 and each Rgis methyl. In some embodiments, n is 1 and Rgis -OH. In some embodiments, n is 1 and Rgis C1-6alkoxy. In some embodiments, n is 1 and Rgis methoxy. In some embodiments, n is 2, one of Rgis methyl, and the other of Rgis –OH.

[0081] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A- I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), or (A-I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R4and R5are independently H.

[0082] In some embodiments of the compound of formula (A) or formula (A-I), or a pharmaceutically acceptable salt of any of the foregoing, R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl. In some embodiments, R4and R5are taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl. In some 44ny-2734555Docket No.: 79275-20026.40 embodiments, R4and R5are taken, together with the atoms to which they are attached, to form cyclobutyl.

[0083] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), or a pharmaceutically acceptable salt of any of the foregoing, R4and R5are taken, together with the atoms to which they are attached, to form cyclobutyl, wherein the compound is of formula (A-I-H1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0084] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A2), or a pharmaceutically acceptable salt of any of the foregoing, R4and R5are taken, together with the atoms to which they are attached, to form cyclobutyl, wherein the compound is of formula (A-I-H2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0085] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A3), or a pharmaceutically acceptable salt of any of the foregoing, R4and R5are taken, together with the atoms to which they are attached, to form cyclobutyl, wherein the compound is of formula (A-I-H3):ny-2734555Docket No.: 79275-20026.40thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0086] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-H1), (A-I-H2), or (A-I-H3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1and R2are each H. In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-H1), (A-I-H2), or (A-I-H3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rxis H. In some embodiments, R1, R2, and Rxare each H.

[0087] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A- I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), (A-I-G3), (A-I-H1), (A-I-H2), or (A-I-H3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R3is H, -OH, halo, or C1-6alkoxy. In some embodiments, R3is H. In some embodiments, R3is -OH, halo, or C1-6alkoxy. In some embodiments, R3is H or -OH. In some embodiments, R3is -OH. In some embodiments, R3is halo. In some embodiments, R3is C1-6alkoxy. In some embodiments, R3is methoxy.

[0088] In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A- I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), or (A-I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R3, R4, and R5are each H. In some embodiments of the compound of formula (A) or formula (A-I), such as a compound of formula (A-I-H1), (A-I-H2), or (A-I-H3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R1, R2, R3, and Rxare each H. 46ny-2734555Docket No.: 79275-20026.40

[0089] In some embodiments of the compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L is(A) is a compound of formula (A-II):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0090] In some embodiments of the compound of formula (A) or formula (A-II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, E is O, wherein the compound is of formula (A-II-A1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.ny-2734555Docket No.: 79275-20026.40

[0091] In some embodiments of the compound of formula (A) or formula (A-II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, E is NH, wherein the compound is of formula (A-II-A2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, E is N(C1-6alkyl). In some embodiments, E is N(CH3).

[0092] In some embodiments of the compound of formula (A) or formula (A-II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, E is CH2, wherein the compound is of formula (A-II-A3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, E is CH(C1-6alkyl). In some embodiments, E is CH(CH3).

[0093] In some embodiments of the compound of formula (A) or formula (A-II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl. In some embodiments, Ryis taken together with R7, and the atoms to which they are attached, to form a 3-6 membered heterocyclyl. In some embodiments, Ryis taken together with R7, and the atoms to which they are attached, to form a 5-8 membered heterocyclyl. In some embodiments, Ryis taken together with R7, and the atoms to which they are attached, to form a 5-6 membered heterocyclyl. In some embodiments, Ryis taken together with R7, and the 48ny-2734555Docket No.: 79275-20026.40 atoms to which they are attached, to form a 5-membered heterocyclyl. In some embodiments, Ryis taken together with R7, and the atoms to which they are attached, to form a 6-membered heterocyclyl.

[0094] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A1), (A-II-A2), or (A-II-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, p is 1. In other embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A1), (A-II- A2), or (A-II-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, p is 0.

[0095] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ryis taken together with R7, and the atoms to which they are attached, to form a 6-membered heterocyclyl, and p is 1, wherein the compound is of formula (A-II-B1):tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0096] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ryis taken together with R7, and the atoms to which they are attached, to form a 5-membered heterocyclyl, and p is 0, wherein the compound is of formula (A-II-C1): 49ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0097] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ryis taken together with R7, and the atoms to which they are attached, to form a 5-membered heterocyclyl, and p is 0, wherein the compound is of formula (A-II-C2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0098] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ryis taken together with R7, and the atoms to which they are attached, to form a 5-membered heterocyclyl, and p is 0, wherein the compound is of formula (A-II-C3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.ny-2734555Docket No.: 79275-20026.40

[0099] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ryis taken together with R7, and the atoms to which they are attached, to form a 6-membered heterocyclyl, and p is 0, wherein the compound is of formula (A-II-D1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0100] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ryis taken together with R7, and the atoms to which they are attached, to form a 6-membered heterocyclyl, and p is 0, wherein the compound is of formula (A-II-D2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0101] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ryis taken together with R7, and the atoms to which they are attached, to form a 6-membered heterocyclyl, and p is 0, wherein the compound is of formula (A-II-D3):ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0102] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II-C1), (A-II-C2), (A-II- C3), (A-II-D1), (A-II-D2), or (A-II-D3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R6is -OH. In some embodiments, R6is -OH, R8is C1-6alkyl, and R9is C1-6alkyl. In some embodiments, R6is -OH, R8is methyl, and R9is methyl. In some embodiments, R6is -OH, R8is H, and R9is H.

[0103] In some embodiments of the compound of formula (A) or formula (A-II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of R8and R9is taken together with R10, and the atoms to which they are attached, to form a C3-8cycloalkyl. In some embodiments, one of R8and R9is taken together with R10, and the atoms to which they are attached, to form a C3-6cycloalkyl. In some embodiments, one of R8and R9is taken together with R10, and the atoms to which they are attached, to form a C3-4cycloalkyl. In some embodiments, one of R8and R9is taken together with R10, and the atoms to which they are attached, to form cyclobutyl.

[0104] In some embodiments of the compound of formula (A) or formula (A-II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of R8and R9is taken together with R10, and the atoms to which they are attached, to form cyclobutyl, wherein the compound is of formula (A-II-E1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.ny-2734555Docket No.: 79275-20026.40

[0105] In some embodiments of the compound of formula (A) or formula (A-II), such as a compound of formula (A-II-E1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R6is -OH and R7is H.

[0106] In some embodiments of the compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L iswherein the compound is of formula (A-III):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0107] In some embodiments of the compound of formula (A) or formula (A-III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, G is O, wherein the compound is of formula (A-III-A1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0108] In some embodiments of the compound of formula (A) or formula (A-III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, G is NH, wherein the compound is of formula (A-III-A2):ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, G is N(C1-6alkyl). In some embodiments, G is N(CH3).

[0109] In some embodiments of the compound of formula (A) or formula (A-III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, G is CH2, wherein the compound is of formula (A-III-A3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, G is CH(C1-6alkyl).

[0110] In some embodiments of the compound of formula (A) or formula (A-III), such as a compound of formula (A-III-A1), (A-III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rzis H. In some embodiments, Rzis C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more C3-8cycloalkyl. In some embodiments, Rzis unsubstituted C1-6alkyl. In some embodiments, Rzis unsubstituted C1-3alkyl. In some embodiments, Rzis unsubstituted methyl or unsubstituted ethyl. In some embodiments, Rzis unsubstituted ethyl. In some embodiments, Rzis C1-6alkyl, wherein the C1-6alkyl is substituted with one or more C3-8cycloalkyl. In some embodiments, Rzis C1-6alkyl, wherein the C1-6alkyl is substituted with one or more C3-6cycloalkyl. In some embodiments, Rzis methyl, wherein the methyl is substituted with cyclopropyl.

[0111] In some embodiments of the compound of formula (A) or formula (A-III), such as a compound of formula (A-III-A1), (A-III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of R11and R12is -OH and the other of R11and R12is H, halo, or C1-6alkyl. In some embodiments, one of R11and R12is 54ny-2734555Docket No.: 79275-20026.40 -OH and the other of R11and R12is H. In some embodiments, one of R11and R12is -OH and the other of R11and R12is C1-6alkyl. In some embodiments, one of R11and R12is -OH and the other of R11and R12is methyl.

[0112] In some embodiments of the compound of formula (A) or formula (A-III), such as a compound of formula (A-III-A1), (A-III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R13and R14are both H. In some embodiments, R13and R14are both C1-6alkyl. In some embodiments, R13and R14are both methyl. In some embodiments, one of R13and R14is H and the other of R13and R14is C1-6alkyl or C3-8cycloalkyl. In some embodiments, one of R13and R14is H and the other of R13and R14is C1-6alkyl. In some embodiments, one of R13and R14is H and the other of R13and R14is methyl. In some embodiments, one of R13and R14is H and the other of R13and R14is C3-8cycloalkyl. In some embodiments, one of R13and R14is H and the other of R13and R14is cyclopropyl. In some embodiments, R13and R14are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl. In some embodiments, R13and R14are taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl. In some embodiments, R13and R14are taken, together with the atoms to which they are attached, to form a 5-8 membered heterocyclyl. In some embodiments, R13and R14are taken, together with the atoms to which they are attached, to form a 5-6 membered heterocyclyl. In some embodiments, R13and R14are taken, together with the atoms to which they are attached, to form tetrahydrofuranyl.

[0113] In some embodiments of the compound of formula (A), such as a compound of formula (A-I), (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A-I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I- G1), (A-I-G2), (A-I-G3), (A-I-H1), (A-I-H2), (A-I-H3), (A-II), (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II-C1), (A-II-C2), (A-II-C3), (A-II-D1), (A-II-D2), (A-II-D3), (A-II-E1), (A-III), (A-III-A1), (A-III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X1, X2, X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, provided that at least one of X1, X2, X3, and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, three of X1, X2, X3, and X4are H and one of X1, X2, X3, and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-55ny-2734555Docket No.: 79275-20026.406alkoxy is optionally substituted with one or more halo. In some embodiments, two of X1, X2, X3, and X4are H and two of X1, X2, X3, and X4are independently halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.

[0114] In some embodiments of the compound of formula (A), such as a compound of formula (A-I), (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A-I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I- G1), (A-I-G2), (A-I-G3), (A-I-H1), (A-I-H2), (A-I-H3), (A-II), (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II-C1), (A-II-C2), (A-II-C3), (A-II-D1), (A-II-D2), (A-II-D3), (A-II-E1), (A-III), (A-III-A1), (A-III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X1and X2are each H, one of X3and X4is H, and the other of X3and X4is halo. In some embodiments, X1and X2are each H, one of X3and X4is H, and the other of X3and X4is chloro.

[0115] In some embodiments of the compound of formula (A), such as a compound of formula (A-I), (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A-I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I- G1), (A-I-G2), (A-I-G3), (A-I-H1), (A-I-H2), (A-I-H3), (A-II), (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II-C1), (A-II-C2), (A-II-C3), (A-II-D1), (A-II-D2), (A-II-D3), (A-II-E1), (A-III), (A-III-A1), (A-III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is H and the other of X1and X2is C1-6alkyl, and X3and X4are each H. In some embodiments, one of X1and X2is H and the other of X1and X2is ethyl, and X3and X4are each H. In some embodiments, one of X1and X2is H and the other of X1and X2is C1-6alkoxy, wherein the C1-6alkoxy is optionally substituted with one or more halo, and X3and X4are each H. In some embodiments, one of X1and X2is H and the other of X1and X2is methoxy, and X3and X4are each H. In some embodiments, one of X1and X2is H and the other of X1and X2is -O-CHF2, and X3and X4are each H. In some embodiments, one of X1and X2is H and the other of X1and X2is -O-CHF2, and one of X3and X4is H and the other of X3and X4is chloro. In some embodiments, one of X1and X2is H and the other of X1and X2is halo, and one of X3and X4is H and the other of X3and X4is halo. In some embodiments, one of X1and X2is H and the other of X1and X2is C1-6alkyl, and one of X3and X4is H and the other of X3and X4is halo. In some embodiments, one of X1ny-2734555Docket No.: 79275-20026.40 and X2is H and the other of X1and X2is methyl, and one of X3and X4is H and the other of X3and X4is halo. In some embodiments, one of X1and X2is H and the other of X1and X2is C1-6alkoxy, one of X3and X4is H and the other of X3and X4is halo. In some embodiments, one of X1and X2is H and the other of X1and X2is methoxy, one of X3and X4is H and the other of X3and X4is halo. In some embodiments, one of X1and X2is H and the other of X1and X2is chloro, and one of X3and X4is H and the other of X3and X4is chloro. In some embodiments, X1and X2are each H, and X3and X4are each halo. In some embodiments, X1and X2are each H, and X3and X4are each chloro. In some embodiments, X1and X2are each H, one of X3and X4is chloro and the other of X3and X4is fluoro. In some embodiments, X1and X2are each H, and one of X3and X4is H and the other of X3and X4is –CN. In some embodiments, X1and X2are each H, and one of X3and X4is H and each of X3and X4is –CN. In some embodiments, X1and X2are each H, and one of X3and X4is C1-6alkyl and the other of X3and X4is –CN. In some embodiments, X1and X2are each H, and one of X3and X4is halo and the other of X3and X4is – CN. In some embodiments, X1and X2are each H, and one of X3and X4is –CF3and the other of X3and X4is –CN. In some embodiments, one of X1and X2is H and the other of X1and X2is C1-6alkyl, one X3and X4is halo and the other of X3and X4is –CN. In some embodiments, X1and X2are each H, one of X3and X4is H and the other of X3and X4is –SF5.

[0116] In some embodiments, the phenyl ring bearing moieties X1, X2, X3, and X4is selected from the group consisting of,X3, and X4is selected from the group consistingny-2734555Docket No.: 79275-20026.40

[0117] In some embodiments of the compound of formula (A), such as a compound of formula (A-I), (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A-I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I- G1), (A-I-G2), (A-I-G3), (A-I-H1), (A-I-H2), (A-I-H3), (A-II), (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II-C1), (A-II-C2), (A-II-C3), (A-II-D1), (A-II-D2), (A-II-D3), (A-II-E1), (A-III), (A-III-A1), (A-III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q is absent. In some embodiments of the compound of formula (A), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (A-B):ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0118] In some embodiments of the compound of formula (A) or formula (A-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y is O, wherein the compound is of formula (A-B-1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0119] In some embodiments of the compound of formula (A), formula (A-B), or formula (A-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each independently H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, two of Ra, Rb, and Rcare independently H, and one of Ra, Rb, and Rcis C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, two of Ra, Rb, and Rcare independently H, and one

[0120] In some embodiments of the compound of formula (A), formula (A-B), or formula (A-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-6 membered heterocyclyl, and the other of Ra, Rb, and 59ny-2734555Docket No.: 79275-20026.40 Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form oxetanyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl.

[0121] In some embodiments of the compound of formula (A), formula (A-B), or formula (A-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each H, wherein the compound is of formula (A-B-2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0122] In some embodiments of the compound of formula (A), formula (A-B), formula (A-B-1), or formula (A-B-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is H and the other of X1and X2is chloro, X3is H, and X4is H, wherein the compound is of formula (A-B-3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0123] In some embodiments of the compound of formula (A) or formula (A-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y is -N(C1-6alkyl). In some embodiments, Y is -N(CH3), wherein the compound is of formula (A-B-4): 60ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0124] In some embodiments of the compound of formula (A), formula (A-B), or formula (A-B- 4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each independently H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, two of Ra, Rb, and Rcare independently H, and one of Ra, Rb, and Rcis C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, two of Ra, Rb, and Rcare independently H, and one of Ra, Rb, and Rcis,,

[0125] In some embodiments of the compound of formula (A), formula (A-B), or formula (A-B- 4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form oxetanyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, any two of Ra, Rb, and Rcare taken, together with theatoms to which they are attached, to form azetidinyl, and the other of Ra, Rb, and Rc is H or C1-61ny-2734555Docket No.: 79275-20026.406alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl.

[0126] In some embodiments of the compound of formula (A), formula (A-B), or formula (A-B- 4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each H, wherein the compound is of formula (A-B-5):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0127] In some embodiments of the compound of formula (A), formula (A-B), formula (A-B-4), or formula (A-B-5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is H and the other of X1and X2is chloro, X3is H, and X4is H, wherein the compound is of formula (A-B-6):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0128] In some embodiments of the compound of formula (A), such as a compound of formula (A-I), (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A-I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I- G1), (A-I-G2), (A-I-G3), (A-I-H1), (A-I-H2), (A-I-H3), (A-II), (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II-C1), (A-II-C2), (A-II-C3), (A-II-D1), (A-II-D2), (A-II-D3), (A-II-E1), (A-III), (A-III-A1), (A-III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Q is -N(C1-6alkyl). In some embodiments, Q is -N(CH3). In some embodiments of the compound of formula (A), or any 62ny-2734555Docket No.: 79275-20026.40 variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (A-C):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0129] In some embodiments of the compound of formula (A) or formula (A-C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Ra, Rb, and Rcare each independently H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, two of Ra, Rb, and Rcare independently H, and one of Ra, Rb, and Rcis C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, two of Ra, Rb, and Rcare

[0130] In some embodiments of the compound of formula (A) or formula (A-C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more - OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl. In some embodiments, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form oxetanyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl 63ny-2734555Docket No.: 79275-20026.40 of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or - S(O)2-C1-6alkyl.

[0131] In some embodiments of the compound of formula (A) or formula (A-C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each H, wherein the compound is of formula (A-C-1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0132] In some embodiments of the compound of formula (A), formula (A-C), or formula (A-C- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is H and the other of X1and X2is chloro, X3is H, and X4is H, wherein the compound is of formula (A-C-2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0133] In some embodiments of the compound of formula (A), such as a compound of formula (A-B), (A-B-1), (A-B-2), (A-B-3), (A-B-4), (A-B-5), (A-B-6), (A-C), (A-C-1), or (A-C-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Lany embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (A-I), (A-I-A1), (A-I-A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A-I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I- E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), (A-I-G3), (A-I-H1), (A-I-H2), (A-I-H3), (A-II), (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II-C1), (A-II-C2), (A- II-C3), (A-II-D1), (A-II-D2), (A-II-D3), (A-II-E1), (A-III), (A-III-A1), (A-III-A2), or (A-III- 64ny-2734555Docket No.: 79275-20026.40 A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0134] In some embodiments of the compound of formula (A), such as a compound of formula (A-B), (A-B-1), (A-B-2), (A-B-3), (A-B-4), (A-B-5), (A-B-6), (A-C), (A-C-1), or (A-C-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Lany embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (A-I), (A-I-A1), (A-I- A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A-I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), (A-I- G3), (A-I-H1), (A-I-H2), (A-I-H3), (A-II), (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II- C1), (A-II-C2), (A-II-C3), (A-II-D1), (A-II-D2), (A-II-D3), (A-II-E1), (A-III), (A-III-A1), (A- III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0135] In some embodiments of the compound of formula (A), such as a compound of formula (A-B), (A-B-1), (A-B-2), (A-B-3), (A-B-4), (A-B-5), (A-B-6), (A-C), (A-C-1), or (A-C-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Lany embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (A-I), (A-I-A1), (A-I- A2), (A-I-A3), (A-I-B1), (A-I-B2), (A-I-B3), (A-I-C1), (A-I-C2), (A-I-C3), (A-I-D1), (A-I-D2), (A-I-D3), (A-I-E1), (A-I-E2), (A-I-E3), (A-I-F1), (A-I-F2), (A-I-F3), (A-I-G1), (A-I-G2), (A-I- G3), (A-I-H1), (A-I-H2), (A-I-H3), (A-II), (A-II-A1), (A-II-A2), (A-II-A3), (A-II-B1), (A-II- C1), (A-II-C2), (A-II-C3), (A-II-D1), (A-II-D2), (A-II-D3), (A-II-E1), (A-III), (A-III-A1), (A- III-A2), or (A-III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.ny-2734555Docket No.: 79275-20026.40

[0136] In some embodiments, the compound of Formula (A) is a compound of formula

[0137] In some embodiments of the compound of formula (A), or a pharmaceutically acceptable salt of any of the foregoing, L is selected from the group consisting of,,66ny-2734555Docket No.: 79275-20026.40to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4.

[0138] In some embodiments of the compound of formula (A), or a pharmaceutically acceptable salt of any of the foregoing, L and the phenyl ring bearing moieties X1-X4together form any-2734555Docket No.: 79275-20026.40ny-2734555Docket No.: 79275-20026.40

[0139] In some embodiments of the compound of formula (A), or a pharmaceutically acceptable salt of any of the foregoing, wherein the phenyl ring bearing Q is selected from the group 69ny-2734555Docket No.: 79275-20026.40

[0140] In some embodiments of the compound of formula (A), or a pharmaceutically acceptable salt of any of the foregoing, L and the phenyl ring bearing moieties Q together form a structure selected from the group consistingny-2734555Docket No.: 79275-20026.40ny-2734555Docket No.: 79275-20026.40ny-2734555Docket No.: 79275-20026.40

[0141] It is to be understood that any variation or embodiment of X1, X2, X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, Ra, Rb, Rc, Rg, Rx, Ry, Rz, n, p, A, E, G, L, Q, and Y provided herein can be combined with every other variation or embodiment of X1, X2, X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, Ra, Rb, Rc, Rg, Rx, Ry, Rz, n, p, A, E, G, L, Q, and Y, the same as if each and every combination had been individually and specifically described.

[0142] In some embodiments of the compound of formula (A), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of FIG.1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0143] In some embodiments, a compound of formula (A) is selected from the group consisting of: 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane; 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol; N-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide; N-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-N- methylmethanesulfonamide; 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine; 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine; 1-(3-chlorophenyl)-2-(3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol; 1-(3-chlorophenyl)-2-(3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol; 1-(2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine; 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol; 1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine; 1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine; 73ny-2734555Docket No.: 79275-20026.40 1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; N-(4-(1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-((3-chlorophenethyl)amino)cyclobutoxy)phenyl)-N-methylmethanesulfonamide; N-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide; 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; 1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; 1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; N-(4-(3-((3-chlorophenethyl)(cyclopropylmethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-((3-chlorophenethyl)(ethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-((3-chlorophenethyl)amino)-2-methylpropoxy)phenyl)-N-methylmethanesulfonamide; 1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; N-(4-(3-(3-(3-chlorophenyl)cyclobutyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; 1-(3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; N-(4-((2)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((2)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide; N-(4-(3-((1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-((2,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide;ny-2734555Docket No.: 79275-20026.40 N-(4-(3-((3,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-((3-(3-chlorobenzyl)tetrahydrofuran-3-yl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; 1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; 1-((1-(3-chlorophenyl)-2-methylpropan-2-yl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; N-(4-(2-hydroxy-3-((2-methoxyphenethyl)amino)propoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(3-((3-cyanophenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide; N-(4-(3-((2-ethylphenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide; N-(4-(3-((2-(difluoromethoxy)phenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; 1-((2-(3-chlorophenyl)-1-cyclopropylethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-N- methylmethanesulfonamide; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol; 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol; 1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine; 1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;ny-2734555Docket No.: 79275-20026.40 2-[4-({1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl}methoxy)benzenesulfonyl]ethan-1- ol; 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol; 2-[4-({1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl}methoxy)benzenesulfonyl]ethan-1- ol; 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol; 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol; 1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine; 1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine; 1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine; 1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidine; 1-[2-(3,5-dichlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine; 1-[2-(5-chloro-2-methylphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}piperazine; 3-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile; 3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile; 3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile; 3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; 3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile; 3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile; 3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile; 1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine; 3-chloro-5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile;ny-2734555Docket No.: 79275-20026.40 1-(3-chlorophenyl)-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethan-1- ol; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; 3-chloro-5-(2-{3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl}ethyl)benzonitrile; 3-chloro-5-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; 3-chloro-5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-chloro-5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile; 1-(3-chlorophenyl)-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethan-1- ol; 1-(3-chlorophenyl)-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethan-1- ol; 3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-chloro-5-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-chloro-5-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-1-[2-(3-chlorophenyl)ethyl]piperazine; 3-chloro-5-[2-(4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin- 1-yl)ethyl]benzonitrile; 3-chloro-5-[2-(4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1- yl)ethyl]benzonitrile;ny-2734555Docket No.: 79275-20026.40 3-chloro-5-[2-(3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1- yl)ethyl]benzonitrile; 3-fluoro-5-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-[(4-methanesulfonylphenoxy)methyl]-4-methyl-1-{2-[3-(pentafluoro-lambda6- sulfanyl)phenyl]ethyl}pyrrolidine; 3-chloro-5-[2-(3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}-4- methylpyrrolidin-1-yl)ethyl]benzonitrile; 3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 1-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine; 3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 1-{2-[5-chloro-2-(difluoromethoxy)phenyl]ethyl}-3-[(4- methanesulfonylphenoxy)methyl]piperazine; 1-(3-chlorophenyl)-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethan-1- ol; 1-(3-chlorophenyl)-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethan-1- ol; 3-chloro-5-[2-(3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1- yl)ethyl]benzonitrile; 1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; 3-[2-(4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1- yl)ethyl]benzonitrile; 3-chloro-5-(1-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}propan-2- yl)benzonitrile;ny-2734555Docket No.: 79275-20026.40 3-[2-(3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1- yl)ethyl]benzonitrile; 3-chloro-5-[2-(3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin- 1-yl)ethyl]benzonitrile; 3-chloro-5-(1-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}propan-2- yl)benzonitrile; 3-chloro-5-(1-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}propan-2- yl)benzonitrile; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; 3-chloro-5-(1-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}propan-2- yl)benzonitrile; 5-chloro-3-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)-2- methylbenzonitrile; 5-chloro-3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)-2- methylbenzonitrile; 3-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-chloro-5-(1-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}propan-2- yl)benzonitrile; 3-chloro-5-[2-(3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}piperazin-1- yl)ethyl]benzonitrile; 3-(2-{3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl}ethyl)-5- (trifluoromethyl)benzonitrile; 3-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)-5- methylbenzonitrile; 3-[2-(3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]benzonitrile; 3-chloro-5-[2-(3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}piperazin-1- yl)ethyl]benzonitrile; 5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzene-1,3- dicarbonitrile;ny-2734555Docket No.: 79275-20026.40 5-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzene-1,3- dicarbonitrile; 3-[2-(4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl)ethyl]-5- chlorobenzonitrile; 3-[2-(3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]-5- chlorobenzonitrile; 3-bromo-5-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-[2-(4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl)ethyl]benzonitrile; 3-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-{2-[3-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin- 1-yl]ethyl}benzonitrile; 3-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzonitrile; 3-{2-[3-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin- 1-yl]ethyl}benzonitrile; 3-{2-[3-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin- 1-yl]ethyl}benzonitrile; 3-{2-[2-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin- 1-yl]ethyl}benzonitrile; 5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzene-1,3-dicarbonitrile; 5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzene-1,3-dicarbonitrile; 5-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzene-1,3-dicarbonitrile; 80ny-2734555Docket No.: 79275-20026.40 5-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl}ethyl)benzene-1,3-dicarbonitrile; 3-{2-[2-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin- 1-yl]ethyl}benzonitrile; 3-{2-[2-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin- 1-yl]ethyl}benzonitrile; 5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl}ethyl)benzene-1,3-dicarbonitrile; 3-chloro-5-{2-[3-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)piperazin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[3-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)piperazin-1- yl]ethyl}benzonitrile; and 3-chloro-5-{2-[3-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)piperazin-1- yl]ethyl}benzonitrile, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Isotopically labeled forms of any of the foregoing are also embraced, such as deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein. Mixtures of any of the foregoing are also embraced and described. Prodrugs of any of the foregoing are also embraced herein.

[0144] In some embodiments, a compound of formula (A) is selected from the group consisting of: 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane; (R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane; (S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane; 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol; (R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol; (S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol; N-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide; (S)-N-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide; (R)-N-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide; 81ny-2734555Docket No.: 79275-20026.40 N-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-N- methylmethanesulfonamide; (R)-N-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-N- methylmethanesulfonamide; (S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine; (R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine; (R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine; (S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine; 1-(3-chlorophenyl)-2-((S)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol; (R)-1-(3-chlorophenyl)-2-((S)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol; (S)-1-(3-chlorophenyl)-2-((S)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol; 1-(3-chlorophenyl)-2-((R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol; (R)-1-(3-chlorophenyl)-2-((R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol; (S)-1-(3-chlorophenyl)-2-((R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol; (S)-1-((R)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4- (methylsulfonyl)phenoxy)methyl)piperidine; (S)-1-((S)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4- (methylsulfonyl)phenoxy)methyl)piperidine; (R)-1-((R)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4- (methylsulfonyl)phenoxy)methyl)piperidine; (R)-1-((S)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4- (methylsulfonyl)phenoxy)methyl)piperidine; rac-trans-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol; rac-cis-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol; (3S,4R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol; (3R,4R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol; (3R,4S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol; (3S,4S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol; rac-trans-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine; 82ny-2734555Docket No.: 79275-20026.40 rac-cis-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine; (3S,4R)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine; (3R,4R)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine; (3R,4S)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine; (3S,4S)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine; 1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine; (S)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine; (R)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine; 1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine; (S)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine; (R)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; rac-trans-N-(4-((1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(((3S,4S)-1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-N- methylmethanesulfonamide; N-(4-(((3R,4R)-1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-N- methylmethanesulfonamide; trans-N-(4-(3-((3-chlorophenethyl)amino)cyclobutoxy)phenyl)-N-methylmethanesulfonamide; (S)-N-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-N- methylmethanesulfonamide; (R)-N-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-N- methylmethanesulfonamide; (S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; rac-trans-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; rac-trans-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; rac-cis-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; (2R,4S)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; (2R,4R)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; (2S,4R)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; (2S,4S)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine; 83ny-2734555Docket No.: 79275-20026.40 (S)-N-(4-(3-((3-chlorophenethyl)(cyclopropylmethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-(3-((3-chlorophenethyl)(ethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (R)-N-(4-(3-((3-chlorophenethyl)amino)-2-methylpropoxy)phenyl)-N- methylmethanesulfonamide; (2S)-1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; (S)-1-((S)-2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; (S)-1-((R)-2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; N-(4-((S)-3-((trans-3-(3-chlorophenyl)cyclobutyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (S)-1-((trans-3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; (R)-1-((trans-3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; N-(4-((2S)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((S)-3-((S)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((S)-3-((R)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((2R)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((R)-3-((S)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((R)-3-((R)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)- N-methylmethanesulfonamide; N-(4-((2S)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((S)-3-((S)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((S)-3-((R)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; 84ny-2734555Docket No.: 79275-20026.40 N-(4-((2R)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((R)-3-((S)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((R)-3-((R)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((2S)-3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((S)-3-((S)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((S)-3-((R)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((2R)-3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((R)-3-((R)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((R)-3-((S)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (R)-N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((R)-3-(((S)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((R)-3-(((R)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-(3-((2,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-(3-((3,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide;ny-2734555Docket No.: 79275-20026.40 N-(4-((2R)-3-((3-(3-chlorobenzyl)tetrahydrofuran-3-yl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (S)-1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; (R)-1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol; N-(4-((S)-3-(((S)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((S)-3-(((R)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (R)-1-((1-(3-chlorophenyl)-2-methylpropan-2-yl)amino)-3-(4-(methylsulfonyl)phenoxy)propan- 2-ol; (S)-N-(4-(2-hydroxy-3-((2-methoxyphenethyl)amino)propoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-(3-((3-cyanophenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-(3-((2-ethylphenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-(3-((2-(difluoromethoxy)phenethyl)amino)-2-hydroxypropoxy)phenyl)-N- methylmethanesulfonamide; (2R)-1-((2-(3-chlorophenyl)-1-cyclopropylethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan- 2-ol; (R)-N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-N- methylmethanesulfonamide; (S)-N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-N- methylmethanesulfonamide; N-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-N- methylmethanesulfonamide; (R)-N-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-N- methylmethanesulfonamide; (3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}- 4-methylpyrrolidine; 86ny-2734555Docket No.: 79275-20026.40 3-chloro-5-{2-[(3S,4S)-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4- methylpyrrolidin-1-yl]ethyl}benzonitrile; rac-trans-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; (3R,4R)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; (3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4- methylpyrrolidine; 2-(4-{[(3R,4R)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethan-1-ol; 2-(4-{[(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethan-1-ol; 3-chloro-5-[(1S)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidin-1-yl]ethyl]benzonitrile; 3-chloro-5-[(1R)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidin-1-yl]ethyl]benzonitrile; 3-[(1R)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl]benzonitrile; 3-[(1S)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl]benzonitrile; 5-[(1R)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl]benzene-1,3-dicarbonitrile; 5-[(1S)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl]benzene-1,3-dicarbonitrile; 3-chloro-5-{1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin- 1-yl]ethyl}benzonitrile; 3-chloro-5-[(1S)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidin-1-yl]ethyl]benzonitrile; 3-chloro-5-[(1R)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidin-1-yl]ethyl]benzonitrile;ny-2734555Docket No.: 79275-20026.40 1-(3-chlorophenyl)-2-((3S,4S)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1- yl)ethan-1-ol; (1R)-1-(3-chlorophenyl)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin- 1-yl]ethan-1-ol; (1S)-1-(3-chlorophenyl)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin- 1-yl]ethan-1-ol; 3-[1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl]benzonitrile; 3-[(1S)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl]benzonitrile; 3-[(1R)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl]benzonitrile; 5-{1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzene-1,3-dicarbonitrile; 5-[(1R)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl]benzene-1,3-dicarbonitrile; 5-[(1S)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl]benzene-1,3-dicarbonitrile; 5-{2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzene- 1,3-dicarbonitrile; (3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; (2S,5S)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine; rac-cis-3-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; rac-trans-3-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[(2S,4R)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 88ny-2734555Docket No.: 79275-20026.40 3-{2-[(2S,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[(2R,4R)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 5-chloro-3-{2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}- 2-methylbenzonitrile; 3-chloro-5-[(2R)-1-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]propan-2-yl]benzonitrile; 3-chloro-5-[(2S)-1-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]propan-2-yl]benzonitrile; 5-chloro-3-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}- 2-methylbenzonitrile; 5-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzene- 1,3-dicarbonitrile; 3-chloro-5-[1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan- 2-yl]benzonitrile; 3-chloro-5-[(2R)-1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propan-2-yl]benzonitrile; 3-chloro-5-[(2S)-1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propan-2-yl]benzonitrile; 3-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; rac-cis-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; (3R,4S)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; (3S,4R)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; (2R,4S)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidine; (3R,4R)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; 89ny-2734555Docket No.: 79275-20026.40 (3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; 3-{2-[(2R,4S)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[(2R,4S)-2-methyl-4-({4-[methyl(methylimino)oxo-λ⁶- sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(2R,4S)-2-methyl-4-({4-[(R)methyl(methylimino)oxo-λ⁶- sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(2R,4S)-2-methyl-4-({4-[(S)methyl(methylimino)oxo-λ⁶- sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile; (2R,5S)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2- methylpiperidine; 3-{2-[(2R,4S)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}-5- chlorobenzonitrile; 3-{2-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin- 1-yl]ethyl}benzonitrile; (3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methyl-1-{2-[3-(pentafluoro-λ⁶- sulfanyl)phenyl]ethyl}pyrrolidine; 3-chloro-5-{2-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]ethyl}benzonitrile; 3-chloro-5-{2-[(2R,4S)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin- 1-yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S,4S)-3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}-4- methylpyrrolidin-1-yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S,4S)-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4- methylpyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin- 1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-methyl-4-({4-[methyl(methylimino)oxo-λ⁶- sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile; 90ny-2734555Docket No.: 79275-20026.40 3-{2-[(3S,4S)-3-methyl-4-({4-[(R)-methyl(methylimino)oxo-λ⁶- sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-methyl-4-({4-[(S)-methyl(methylimino)oxo-λ⁶- sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}-5- chlorobenzonitrile; 3-chloro-5-{2-[(3S,4S)-3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; rac-trans-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine; (3R,4R)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine; (3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine; (3S,4S)-1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; 3-chloro-5-{2-[(3S)-3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S)-3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}piperazin- 1-yl]ethyl}benzonitrile; (3S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}piperazine; (3S)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-1-[2-(3-chlorophenyl)ethyl]piperazine; 3-chloro-5-{2-[(3S)-3-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S)-3-({4-[(S)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin- 1-yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S)-3-({4-[(R)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin- 1-yl]ethyl}benzonitrile; 91ny-2734555Docket No.: 79275-20026.40 3-chloro-5-{2-[(3S)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}benzonitrile; (3S)-1-[2-(3,5-dichlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine; (3S)-1-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine; (3S)-1-{2-[5-chloro-2-(difluoromethoxy)phenyl]ethyl}-3-[(4- methanesulfonylphenoxy)methyl]piperazine; 3-{2-[(3S)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}-5- (trifluoromethyl)benzonitrile; 3-chloro-5-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-fluoro-5-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-bromo-5-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; (3S)-1-[2-(5-chloro-2-methylphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine; 3-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}-5- methylbenzonitrile; rac-cis-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(2S,4R)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; rac-trans-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-(2-((2R,4R)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1- yl)ethyl)benzonitrile; 3-chloro-5-(2-((2S,4S)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1- yl)ethyl)benzonitrile; rac-cis-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin- 3-ol; 92ny-2734555Docket No.: 79275-20026.40 (3R,4R)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3- methylpyrrolidin-3-ol; (3S,4S)-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-3-ol; rac-trans-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3- methylpyrrolidin-3-ol; (3R,4S)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3- methylpyrrolidin-3-ol; (3S,4R)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3- methylpyrrolidin-3-ol; 1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine; rac-cis-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine; rac-trans-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2- methylpiperazine; (1R)-1-(3-chlorophenyl)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin- 1-yl]ethan-1-ol; and (1S)-1-(3-chlorophenyl)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin- 1-yl]ethan-1-ol, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Isotopically labeled forms of any of the foregoing are also embraced, such as deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein. Mixtures of any of the foregoing are also embraced and described. Prodrugs of any of the foregoing are also embraced herein.

[0145] In some embodiments of the compound of formula (B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of formula (B-I): 93ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0146] In some embodiments of the compound of formula (B) or formula (B-I), or a pharmaceutically acceptable salt of any of the foregoing, Rxand R1are taken together with the atoms to which they are attached to form a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rxand R1are taken together with the atoms to which they are attached to form a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is substituted with n independently selected Rmsubstituents. In some embodiments, Rxand R1are taken together with the atoms to which they are attached to form a 5-7 membered heterocycle, wherein the 5-7 membered heterocycle is substituted with n independently selected Rmsubstituents.

[0147] In some embodiments of the compound of formula (B) or formula (B-I), or a pharmaceutically acceptable salt of any of the foregoing, Rxand R1are taken together with the atoms to which they are attached to form a 5-7 membered heterocycle selected from the group consisting of pyrrolidine, piperidine, azepane, imidazolidine, piperazine, 1,4-diazepane, hexahydropyrimidine, triazinane, triazepane, oxazolidine, morpholine, 1,4-oxazepane, 1,3- oxazinane, 1,4-oxazepane, thiazolidine, thiomorpholine, 1,4-thiazepane, 1,3-thiazinane, and 1,4- thiazepane. In some embodiments, the 5-7 membered heterocycle is selected from the group consisting of pyrrolidine, piperidine, azepane, imidazolidine, piperazine, 1,4-diazepane, and hexahydropyrimidine. In some embodiments, the 5-7 membered heterocycle is selected from the group consisting of pyrrolidine, piperidine, and piperazine.

[0148] In some embodiments of the compound of formula (B) or formula (B-I), or a pharmaceutically acceptable salt of any of the foregoing, Rxand R1are taken together with the atoms to which they are attached to form a 5-membered heterocycle, wherein the 5-membered heterocycle is substituted with n independently selected Rmsubstituents. In some embodiments, 94ny-2734555Docket No.: 79275-20026.40 the 5-membered heterocycle is pyrrolidine. In some embodiments, Rxand R1are taken together with the atoms to which they are attached to form a 6-membered heterocycle, wherein the 6- membered heterocycle is substituted with n independently selected Rmsubstituents. In some embodiments, the 6-membered heterocycle is piperidine, or piperazine. In some embodiments, the 6-membered heterocycle is piperidine. In some embodiments, the 6-membered heterocycle is piperazine.

[0149] In some embodiments of the compound of formula (B) or formula (B-I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-I-A):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein p is 0, 1, or 2, and V1and V2are each independently -CH2-, -NH-, or -O-.

[0150] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), or a pharmaceutically acceptable salt of any of the foregoing, p is 0, 1, or 2, and V1and V2are each independently -CH2-, -NH-, or -O-. In some embodiments, p is 0, and V1and V2are each independently -CH2-, -NH-, or -O-. In some embodiments, p is 1, and V1and V2are each independently -CH2-, -NH-, or -O-. In some embodiments, p is 2, and V1and V2are each independently -CH2-, -NH-, or -O-. In some embodiments, p is 0, 1, or 2, and both of V1and V2are -CH2-. In some embodiments, p is 0, 1, or 2, V1is -CH2-, and V2is -NH-, or -O-. In some embodiments, p is 0, 1, or 2, V1is -NH-, or -O-, and V2is -CH2-. In some embodiments, p is 0, and both of V1and V2are -CH2-. In some embodiments, p is 1, and both of V1and V2are -CH2-. In some embodiments, p is 2, and both of V1and V2are -CH2-. In some embodiments, p is 1, V1is -NH- and V2is -CH2-. In some embodiments, p is 1, V1is -O-, and V2is -CH2-.

[0151] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-I-A1):ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0152] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0-6. In some embodiments, n is an integer from 0-3. In some embodiments, n is 0 or 1. In some embodiments, n is 0. In some embodiments, n is 1.

[0153] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-I-A2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0154] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 0.

[0155] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0-6. In some embodiments, n is an integer from 0-5. In some embodiments, n is an integer from 0-4. In some embodiments, n is an integer from 0-3. In some embodiments, n is an integer from 0-2. In some embodiments, n is 0 or 1. In some embodiments, n is an integer from 1-6. In some embodiments, 96ny-2734555Docket No.: 79275-20026.40 n is an integer from 1-5. In some embodiments, n is an integer from 1-4. In some embodiments, n is an integer from 1-3. In some embodiments, n is 1 or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

[0156] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rmis C1-3alkyl, or C(O)C1-3alkyl, wherein the C1-3alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rmis methyl, or C(O)CH3, wherein the methyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rmis C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rmis methyl. In some embodiments, Rmis -CH2OH. In some embodiments, Rmis C(O)C1-6alkyl. In some embodiments, Rmis C(O)CH3.

[0157] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1 and Rmis C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, n is 1 and Rmis methyl. In some embodiments, n is 1 and Rmis CH2OH. In some embodiments, n is 2 and each Rmis C1-6alkyl. In some embodiments, n is 2 and each Rmis methyl. In some embodiments, n is 1 and Rmis C(O)C1-6alkyl. In some embodiments, n is 1 and Rmis C(O)CH3.

[0158] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2is H, -OH, or C1-6alkyl, wherein the C1-6alkyl of R2is optionally substituted with one or more OH. In some embodiments, R2is H, - OH, or C1-3alkyl, wherein the C1-3alkyl of R2is optionally substituted with one or more OH. In some embodiments, R2is H, -OH, or methyl, wherein the methyl of R2is optionally substituted with one or more OH. In some embodiments, R2is H. In some embodiments, R2is -OH. In some embodiments, R2is methyl. In some embodiments, R2is -CH2OH. 97ny-2734555Docket No.: 79275-20026.40

[0159] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R3is H, or C1-6alkyl, wherein the C1-6alkyl of R3is optionally substituted with one or more OH. In some embodiments, R3is H, or C1-3alkyl, wherein the C1-3alkyl of R3is optionally substituted with one or more -OH. In some embodiments, R3is H, or methyl, wherein the methyl of R3is optionally substituted with one or more -OH. In some embodiments, R3is H. In some embodiments, R3is methyl. In some embodiments, R3is -CH2OH.

[0160] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R2and R3are independently H. In some embodiments, one of R2and R3is H and the other R2and R3is methyl. In some embodiments, R2is OH and R3is H. In some embodiments, one of R2and R3is H and the other R2and R3is methyl. In some embodiments, one of R2and R3is H and the other R2and R3is CH2OH. In some embodiments, one of R2and R3is methyl and the other R2and R3is OH.

[0161] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L is selected from the group consisting98ny-2734555Docket No.: 79275-20026.40, wherein # represents the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, and ## represents the point of attachment to the remainder of the molecule. In some embodiments, L is selected from the group consisting of.

[0162] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L is selected from the group consisting99ny-2734555Docket No.: 79275-20026.40some embodiments, L is selected from the group consisting of100ny-2734555Docket No.: 79275-20026.40

[0163] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-I-A), (B-I-A1), or (B-I-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,wherein # represents the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, and ## represents the point of attachment to the remainder of the molecule. In some embodiments, L is.

[0164] In some embodiments of the compound of formula (B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound of formula (B) is a compound of formula (B-II):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0165] In some embodiments of the compound of formula (B) or formula (B-II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-II-A): 101ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, q is 1, or 2 and r is 0 or 1.

[0166] In some embodiments of the compound of formula (B) or formula (B-II), such as a compound of formula (B-II-A), or a pharmaceutically acceptable salt of any of the foregoing, q is 1, or 2, and r is 0 or 1. In some embodiments, q is 1, and r is 0 or 1. In some embodiments, q is 2, and r is 0 or 1. In some embodiments, both of q and r are 1. In some embodiments, q is 1, and r is 0. In some embodiments, q is 1, and r is 1. In some embodiments, q is 2, and r is 0. In some embodiments, q is 2, and r is 1.

[0167] In some embodiments of the compound of formula (B) or formula (B-II), such as a compound of formula (B-II-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-II-A1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0168] In some embodiments of the compound of formula (B) or formula (B-II), such as a compound of formula (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0-6. In some embodiments, n is an integer from 0-5. In some embodiments, n is an integer from 0-4. In some embodiments, n is an integer from 0-3. In some embodiments, n is an integer from 0-2. In some embodiments, n is 0 or 1. In some embodiments, n is an integer from 1-6. In some embodiments, n is an integer from 1-5. In some embodiments, n is an integer from 1-4. In some embodiments, n is an integer from 102ny-2734555Docket No.: 79275-20026.40 1-3. In some embodiments, n is 1 or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.

[0169] In some embodiments of the compound of formula (B) or formula (B-II), such as a compound of formula (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,wherein # represents the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, and ## represents the point of attachment to the remainder of the molecule. In some embodiments,

[0170] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), or (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X1, and X2are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, both of X1, and X2are H. In some embodiments, one of X1, and X2is H, and the other of X1, and X2is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.

[0171] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), or (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X3and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, both of X3and X4are H. In some embodiments, one of X3and X4is H, and the other of X3and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.

[0172] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), or (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X1, X2, X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl orny-2734555Docket No.: 79275-20026.40 C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, three of X1, X2, X3, and X4are H and one of X1, X2, X3, and X4is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, two of X1, X2, X3, and X4are H and two of X1, X2, X3, and X4are independently H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, two of X1, X2, X3, and X4are H and two of X1, X2, X3, and X4are independently H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-3alkyl or C1-3alkoxy is optionally substituted with one or more halo.

[0173] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), or (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X1and X2are each H, one of X3and X4is H, and the other of X3and X4is halo or -CN. In some embodiments, X1and X2are each H, one of X3and X4is H, and the other of X3and X4is chloro. In some embodiments, X1and X2are each H, one of X3and X4is H, and the other of X3and X4is -CN.

[0174] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), or (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X1and X2are each H, and X3and X4are independently, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, X1and X2are each H, and X3and X4are independently, halo, -CN, C1-3alkyl, C1-3alkoxy, or SF5, wherein the C1-3alkyl or C1-3alkoxy is optionally substituted with one or more halo. In some embodiments, X1and X2are each H, and X3and X4are independently, halo, or –CN. In some embodiments, X1and X2are each H, and X3and X4are independently, Cl, or –CN.

[0175] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), or (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is H, the other of X1and X2is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, and X3and X4are independently, halo, - CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, one of X1and X2is H, the other of X1and X2is halo, -CN, C1-3alkyl, C1-3alkoxy, or SF5, wherein the C1-3alkyl or C1-3alkoxy is optionally 104ny-2734555Docket No.: 79275-20026.40 substituted with one or more halo, and X3and X4are independently, halo, -CN, C1-3alkyl, C1-3alkoxy, or SF5, wherein the C1-3alkyl or C1-3alkoxy is optionally substituted with one or more halo. In some embodiments, one of X1and X2is H, the other of X1and X2is methyl, and X3and X4are independently, halo, -CN, C1-3alkyl, C1-3alkoxy, or SF5, wherein the C1-3alkyl or C1-3alkoxy is optionally substituted with one or more halo. In some embodiments, one of X1and X2is H, the other of X1and X2is methyl, and X3and X4are independently, Cl, or -CN.

[0176] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), or (B-II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the phenyl ring bearing moieties X1, X2, X3, and X4is selected from the group consistingembodiments, the phenyl ring bearing moietiesny-2734555Docket No.: 79275-20026.40 embodiments, the phenyl ring bearing moietiessome embodiments, the phenyl ring bearing moieties

[0177] In some embodiments of the compound of formula (B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-III):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0178] In some embodiments of the compound of formula (B) or formula (B-III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein s is 0, 1, or 2 and t is 0 or 1. 106ny-2734555Docket No.: 79275-20026.40

[0179] In some embodiments of the compound of formula (B) or formula (B-III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein s is 0, 1, or 2 and t is 0 or 1.

[0180] In some embodiments of the compound of formula (B) or formula (B-II), such as a compound of formula (B-II-A), or a pharmaceutically acceptable salt of any of the foregoing, s is 0, 1, or 2, and t is 0 or 1. In some embodiments, s is 0, and t is 0 or 1. q is 1, and r is 0 or 1. In some embodiments, s is 1, and t is 0 or 1. In some embodiments, s is 2, and t is 0 or 1. In some embodiments, both of s and t are 0. In some embodiments, s is 0, and t is 1. In some embodiments, s is 1, and t is 0. In some embodiments, both of s and t are 1. In some embodiments, s is 2, and t is 0. In some embodiments, s is 2, and t is 1.

[0181] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-III-A1):or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.ny-2734555Docket No.: 79275-20026.40

[0182] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-III-B1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0183] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-III-A2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0184] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-III-B2): 108ny-2734555Docket No.: 79275-20026.40or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0185] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-III-A3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0186] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-III-B3):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 109ny-2734555Docket No.: 79275-20026.40

[0187] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0 or 1. In some embodiments, m is 0. In some embodiments, m is 1.

[0188] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), Rdand Reare each independently H or C1-6alkyl. In some embodiments, Rdand Reare each independently H. In some embodiments, Rdand Reare each independently C1-6alkyl. In some embodiments, one of Rdand Reis H and the other of Rdand Reis C1-6alkyl. In some embodiments, one of Rdand Reis H and the other of Rdand Reis methyl.

[0189] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), Rdand Reare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-6 membered heterocycle. In some embodiments, Rdand Reare taken together with the atoms to which they are attached to form a C3-6cycloalkyl. In some embodiments, Rdand Reare taken together with the atoms to which they are attached to form a C3-4cycloalkyl. In some embodiments, Rdand Reare taken together with the atoms to which they are attached to form cyclopropyl. In some embodiments, Rdand Reare taken together with the atoms to which they are attached to form a 3-6 membered heterocycle. In some embodiments, Rdand Reare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-4 membered heterocycle. In some embodiments, Rdand Reare taken together with the atoms to which they are attached to form oxetane.

[0190] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y is O or -N(C1-6alkyl). In some embodiments, Y is O. In some embodiments, Y is -N(C1-6alkyl). In some embodiments, Y is -N(C1-3alkyl). In some embodiments, Y is -N(C3-6alkyl). In some embodiments, the C1-6alkyl of the -N(C1-6alkyl) is optionally substituted with one or more Rgsubstituents. In some embodiments, Rgis, independently at each occurrence, -S(O)2C1-6alkyl. In some embodiments, Rgis independently at 110ny-2734555Docket No.: 79275-20026.40 each occurrence, -S(O)2C1-3alkyl. In some embodiments, Rgis, independently at each occurrence, -S(O)2C3-6alkyl.

[0191] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Z1, Z2, Z3, and Z4are, independently of each other, -N-, -CH- or -C(Rf)-. In some embodiments, three or more of Z1, Z2, Z3, and Z4are -N-. In some embodiments, three or more of Z1, Z2, Z3, and Z4are - C(Rf)-. In some embodiments, at least two of Z1, Z2, Z3, and Z4are independently selected from -N- or -C(Rf)-. In some embodiments, at least two of Z1, Z2, Z3, and Z4are -CH-. In some embodiments, at least one of Z1, Z2, Z3, and Z4is -CH-.

[0192] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Z1, Z2, Z3, and Z4are, independently of each other, -N-, -CH- or -C(Rf)-. In some embodiments, each of Z1, Z2, Z3, and Z4is -CH-. In some embodiments, three of Z1, Z2, Z3, and Z4are -CH- and the other of Z1, Z2, Z3, and Z4is -N-, or -C(Rf)-. In some embodiments, two of Z1, Z2, Z3, and Z4are -CH- and the other two of Z1, Z2, Z3, and Z4are independently -N-, or -C(Rf)-.

[0193] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), Rfis independently at each occurrence, -CN, halo, C1-6alkyl, C1-6alkoxy, or - N(Rj)2, wherein the C1-6alkyl of Rfis optionally substituted with one or more halo. In some embodiments, Rfis independently at each occurrence, -CN, halo, C1-3alkyl, C1-3alkoxy, or - N(Rj)2, wherein the C1-3alkyl of Rfis optionally substituted with one or more halo. In some embodiments, Rfis independently at each occurrence, -CN, Cl, F, I, methyl, -OCH3, NH2, or N(CH3)2, wherein the methyl of Rfis optionally substituted with one or more Cl, F, or I. In some embodiments, Rfis F. In some embodiments, Rfis methyl. In some embodiments, Rfis CF3.

[0194] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- 111ny-2734555Docket No.: 79275-20026.40 A3), or (B-III-B3), the ring bearing Z1, Z2, Z3, and Z4is benzene, pyridine, pyridazine, pyrimidine, pyrazine, or triazine, wherein the benzene, pyridine, pyridazine, pyrimidine, pyrazine, or triazine are optionally substituted. In some embodiments, the ring bearing Z1, Z2, Z3, and Z4is benzene, pyridine, pyridazine, pyrimidine, pyrazine, or triazine. In some embodiments, the ring bearing Z1, Z2, Z3, and Z4is benzene, or pyridine. In some embodiments, the ring bearing Z1, Z2, Z3, and Z4is benzene. In some embodiments, the ring bearing Z1, Z2, Z3, and Z4is pyridine.

[0195] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), the ring bearing Z1, Z2, Z3, and Z4is selected from the group consisting of ,

[0196] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is an integer from 0-6. In some embodiments, n is an integer from 0-5. In some embodiments, n is an integer from 0-4. In some embodiments, n is an integer from 0-3. In some embodiments, n is an integer from 0-2. In some embodiments, n is 0 or 1. In some embodiments, n is an integer from 1-6. In some embodiments, n is an integer from 1-5. In some embodiments, n is an integer from 1-4. In some embodiments, n is an integer from 1-3. In some embodiments, n is 1 or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. 112ny-2734555Docket No.: 79275-20026.40

[0197] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rmis C1-3alkyl, or C(O)C1-3alkyl, wherein the C1-3alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rmis methyl, or C(O)CH3, wherein the methyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rmis C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH. In some embodiments, Rmis methyl. In some embodiments, Rmis –CH2OH. In some embodiments, Rmis C(O)C1-6alkyl. In some embodiments, Rmis C(O)CH3.

[0198] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1 and Rmis C1-6alkyl. In some embodiments, n is 1 and Rmis methyl. In some embodiments, n is 2 and each Rmis C1-6alkyl. In some embodiments, n is 2 and each Rmis methyl. In some embodiments, n is 1 and Rmis C(O)C1-6alkyl. In some embodiments, n is 1 and Rmis C(O)CH3.

[0199] In some embodiments of the compound of formula (B) or formula (B-III), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, n is 1 and Rmis C1-6alkyl. In some embodiments, n is 1 and Rmis methyl.

[0200] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, L is selected from the group consistingny-2734555Docket No.: 79275-20026.40Z2, Z3, and Z4, ### represents the point of attachment to X1or X2, ## represents the point of attachment to the remainder of the molecule, and the dashed line represents a single or double bond. In some embodiments, L is selected from the group consisting

[0201] In some embodiments of the compound of formula (B) or formula (B-I), such as a compound of formula (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III- A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable saltembodiments, L is selected from the group consisting114ny-2734555Docket No.: 79275-20026.40some embodiments, L is selected from the group consisting of

[0202] In some embodiments of the compound of formula (B), such as a compound of formula (B-III), (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), or (B-III- B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, and the other of X1or X2is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, and the other of X1or X2is H.

[0203] In some embodiments of the compound of formula (B), such as a compound of formula (B-III), (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), or (B-III- B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, X3and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, both of X3and X4are H. In some embodiments, one of X3and X4is H, and the other of X3and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.ny-2734555Docket No.: 79275-20026.40

[0204] In some embodiments of the compound of formula (B), such as a compound of formula (B-III), (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), or (B-III- B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the other of X1or X2is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, and X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the other of X1or X2is H, one of X3, and X4is H and the other of X3, and X4is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.

[0205] In some embodiments of the compound of formula (B), such as a compound of formula (B-III), (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), or (B-III- B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the other of X1or X2is H, one of X3and X4is H, and the other of X3and X4is halo or -CN. In some embodiments, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the other of X1or X2is H, one of X3and X4is H, and the other of X3and X4is chloro. In some embodiments, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the other of X1or X2is H, one of X3and X4is H, and the other of X3and X4is -CN.

[0206] In some embodiments of the compound of formula (B), such as a compound of formula (B-III), (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), or (B-III- B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the other of X1or X2is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, one of X3and X4is H, and the other of X3and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo. In some embodiments, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the 116ny-2734555Docket No.: 79275-20026.40 other of X1or X2is halo, -CN, C1-3alkyl, C1-3alkoxy, or SF5, wherein the C1-3alkyl or C1-3alkoxy is optionally substituted with one or more halo, one of X3and X4is H, and the other of X3and X4is halo, -CN, C1-3alkyl, C1-3alkoxy, or SF5, wherein the C1-3alkyl or C1-3alkoxy is optionally substituted with one or more halo. In some embodiments, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the other of X1or X2is halo, or -CN, one of X3and X4is H, and the other of X3and X4is halo, or -CN. In some embodiments, one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, the other of X1or X2is Cl, or -CN, one of X3and X4is H, and the other of X3and X4is Cl, or -CN.

[0207] In some embodiments of the compound of formula (B), such as a compound of formula (B-III), (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), or (B-III- B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the phenyl ring bearing moieties X1, X2, X3, and X4is selected from the group## represent the points of attachment to L.

[0208] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), (B-II-A1), (B-III), (B-III-A), (B-III-B), (B- III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 0. In some embodiments of the compound of formula (B), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-B):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.ny-2734555Docket No.: 79275-20026.40

[0209] In some embodiments of the compound of formula (B) or formula (B-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y is O, wherein the compound is of formula (B-B-1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0210] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each independently H, C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents. In some embodiments, two of Ra, Rb, and Rcare independently H, and one of Ra, Rb, and Rcis C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents.

[0211] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rhis independently at each occurrence, -OH, C1-6alkoxy, -N(Rj)2, C(O)Rk, or - S(O)2C1-6alkyl. In some embodiments, Rhis independently at each occurrence, -OH, C1-6alkoxy, -N(Rj)2, C(O)Rk, or -S(O)2C1-6alkyl; Rjis independently at each occurrence H, C1-6alkyl or C(O)C1-6alkyl; and Rkis, independently at each occurrence C1-6alkyl or C1-6alkoxy. In some embodiments, Rhis independently at each occurrence, -OH, C1-3alkoxy, -N(Rj)2, C(O)Rk, or - S(O)2C1-6alkyl; Rjis independently at each occurrence H, C1-3alkyl or C(O)C1-3alkyl; and Rkis, independently at each occurrence C1-3alkyl or C1-3alkoxy. In some embodiments, Rhis independently at each occurrence, -OH, -OCH3, -N(Rj)2, C(O)Rk, or -S(O)2CH3; Rjis independently at each occurrence H, -CH3or C(O)CH3; and Rkis, independently at each occurrence CH3, or -OCH3. 118ny-2734555Docket No.: 79275-20026.40

[0212] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Riis independently at each occurrence, oxo, C1-6alkyl, or C(O)Rk. In some embodiments, Riis independently at each occurrence, oxo, C1-6alkyl, or C(O)Rk; and Rkis, independently at each occurrence C1-6alkyl or C1-6alkoxy. In some embodiments, Riis independently at each occurrence, oxo, C1-3alkyl, or C(O)Rk; and Rkis, independently at each occurrence C1-3alkyl or C1-3alkoxy. In some embodiments, Riis independently at each occurrence, oxo, CH3, or C(O)Rk; and Rkis, independently at each occurrence CH3or –OCH3.

[0213] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 1), or a stereoisomer or tautomer thereof, two of Ra, Rb, and Rcare independently H, and one of

[0214] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is optionally substituted with one or more Risubstituents, and the other of Ra, Rb, and Rcis H or C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents.

[0215] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is optionally substituted with one or more Risubstituents, and the other of Ra, Rb, and Rcis H or C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents. In some embodiments, any 119ny-2734555Docket No.: 79275-20026.40 two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a oxetanyl, or azetidinyl, wherein the oxetanyl, or azetidinyl is optionally substituted with one or more Risubstituents, and the other of Ra, Rb, and Rcis H or C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents. In some embodiments, any two of Ra, Rb, and Rcare

[0216] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each H, wherein the compound is of formula (B-B-2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0217] In some embodiments of the compound of formula (B) or formula (B-B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y is -N(C1-6alkyl), wherein the C1-6alkyl of the -N(C1-6alkyl) is optionally substituted with one or more Rgsubstituents. In some embodiments, Y is -N(C1-6alkyl), wherein the C1-6alkyl of the - N(C1-6alkyl) is optionally substituted with one or more Rgsubstituents, wherein the compound is of formula (B-B-3):ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R8is C1-6alkyl, wherein the C1-6alkyl of R8is optionally substituted with one or more Rgsubstituents.

[0218] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, R8is C1-6alkyl, wherein the C1-6alkyl of R8is optionally substituted with one or more Rgsubstituents. In some embodiments, R8is C1-3alkyl, wherein the C1-3alkyl of R8is optionally substituted with one or more Rgsubstituents. In some embodiments, R8is methyl, wherein the methyl of R8is optionally substituted with one or more Rgsubstituents.

[0219] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Rgis, independently at each occurrence, -S(O)2C1-6alkyl. In some embodiments, Rgis, independently at each occurrence, -S(O)2C1-3alkyl. In some embodiments, Rgis, independently at each occurrence, -S(O)2CH3. In some embodiments, R8is methyl. In some embodiments, R8is.

[0220] In some embodiments of the compound of formula (B), formula (B-B), or formula (B-B- 3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each H, wherein the compound is of formula (B-B-4):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 121ny-2734555Docket No.: 79275-20026.40

[0221] In some embodiments of the compound of formula (B), such as a compound of formula (B-I), (B-I-A), (B-I-A1), (B-I-A2), (B-II), (B-II-A), (B-II-A1), (B-III), (B-III-A), (B-III-B), (B- III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), or (B-III-B3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, m is 1. In some embodiments of the compound of formula (B), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-C):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0222] In some embodiments of the compound of formula (B) or formula (B-C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Ra, Rb, and Rcare each H, wherein the compound is of formula (B-C-1):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0223] In some embodiments of the compound of formula (B), formula (B-C), or formula (B-C- 1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, Y is O, wherein the compound is of formula (B-C-2):ny-2734555Docket No.: 79275-20026.40stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0224] In some embodiments of the compound of formula (B) or formula (B-I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-D-1):tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein p is 0, 1, or 2, and V1and V2are each independently -CH2-, -NH-, or -O-.

[0225] In some embodiments of the compound of formula (B) or formula (B-II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-D-2):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, q is 1, or 2 and r is 0 or 1.ny-2734555Docket No.: 79275-20026.40

[0226] In some embodiments of the compound of formula (B) or formula (B-III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-D-3A):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein s is 0, 1, or 2 and t is 0 or 1.

[0227] In some embodiments of the compound of formula (B) or formula (B-III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-D-3B):stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein s is 0, 1, or 2 and t is 0 or 1.

[0228] In some embodiments of the compound of formula (B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound of formula (B) is a compound of formula (B-E-Ia), (B-E-Ib), (B-E-IIa), (B-E-IIb), (B-E-IIIa), (B-E-IIIb), (B- E-IVa), (B-E-IVb), (B-E-Va), (B-E-Vb), (B-E-VIa), (B-E-VIb), (B-E-VIIa), or (B-E-VIIb):ny-2734555Docket No.: 79275-20026.40ny-2734555Docket No.: 79275-20026.40 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0229] In some embodiments of the compound of formula (B), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-C), (B-C-1), (B-C-2), (B-E-Ia), (B-E-Ib), (B-E-IIa), (B-E-IIb), (B-E-IIIa), (B-E-IIIb), (B-E-IVa), (B-E-IVb), (B-E-Va), (B-E-Vb), (B-E-VIa), (B-E-VIb), (B-E- VIIa), or (B-E-VIIb), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,any embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (B-I), (B-I-A1), (B-I-A2), (B-D-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0230] In some embodiments of the compound of formula (B), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-C), (B-C-1), (B-C-2), (B-E-Ia), (B-E-Ib), (B-E-IIa), (B-E-IIb), (B-E-IIIa), (B-E-IIIb), (B-E-IVa), (B-E-IVb), (B-E-Va), (B-E-Vb), (B-E-VIa), (B-E-VIb), (B-E- VIIa), or (B-E-VIIb), or a stereoisomer or tatomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (B-II), (B-II-A), (B-II-A1), or (B-D-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0231] In some embodiments of the compound of formula (B), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-C), (B-C-1), (B-C-2), (B-E-Ia), (B-E-Ib), (B-E-IIa), (B-E-IIb), (B-E-IIIa), (B-E-IIIb), (B-E-IVa), (B-E-IVb), (B-E-Va), (B-E-Vb), (B-E-VIa), (B-E-VIb), (B-E- VIIa), or (B-E-VIIb), or a stereoisomer or tatomer thereof, or a pharmaceutically acceptable saltny-2734555Docket No.: 79275-20026.40 of any of the foregoing,any embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (B-III), (B-III-A), (B-III-B), (B-III-A1), (B-III-B1), (B-III-A2), (B-III-B2), (B-III-A3), (B-III-B3), (B-D-3A), or (B-D-3B), or a stereoisomer or tautomer thereof, or a pharmaceutically

[0232] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L is selected from the group consisting of,,ny-2734555Docket No.: 79275-20026.40the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, and ## represents the point of attachment to the remainder of the molecule. In some embodiments, L is selected from the groupny-2734555Docket No.: 79275-20026.40

[0233] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing,, wherein # represents the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, and ## represents the point of attachment to the remainder of the molecule. In some embodiments,

[0234] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing,, wherein # represents the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, and ## represents the point of attachment to the remainder of the molecule. In some embodiments,.

[0235] In some embodiments of the compound of formula (B), or a pharmaceutically acceptableny-2734555Docket No.: 79275-20026.40wherein # represents the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, ### represents the point of attachment to X1or X2, ## represents the point of attachment to the remainder of the molecule, and the dashed line represents a single or double bond. In some embodiments, L is selected from the group consistingembodiments, L is selected from the group consisting,L is selected from the group consisting of

[0236] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the phenyl ring bearing moieties X1-X4together form any-2734555Docket No.: 79275-20026.40ny-2734555Docket No.: 79275-20026.40

[0237] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the phenyl ring bearing moieties X1-X4together form a

[0238] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the phenyl ring bearing moieties X1-X4together form.

[0239] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the phenyl ring bearing moieties X1-X4together form any-2734555Docket No.: 79275-20026.40 structure selected from the group consisting

[0240] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing Z1-Z4is selected from the group consisting ofny-2734555Docket No.: 79275-20026.40

[0241] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing Z1-Z4is selected from the group consisting of

[0242] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing Z1-Z4is selected from the group consisting of

[0243] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing Z1-Z4is selected from the group consisting of

[0244] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing

[0245] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing Z1-Z4is.

[0246] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing Z1-Z4is.ny-2734555Docket No.: 79275-20026.40

[0247] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing

[0248] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the ring bearing Z1-Z4is selected from the group consisting of

[0249] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form a structure selected fromny-2734555Docket No.: 79275-20026.40

[0250] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form.

[0251] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form a structure selected fromny-2734555Docket No.: 79275-20026.40

[0252] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form.

[0253] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form a structure selected fromrepresents the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, ### represents the point of attachment to X1or X2, ## represents the point of attachment to the remainder of the molecule, and the dashed line represents a single or double bond..

[0254] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form any-2734555Docket No.: 79275-20026.40wherein # represents the point of attachment to the ring bearing Z1, Z2, Z3, and Z4, ### represents the point of attachment to X1or X2, ## represents the point of attachment to the remainder of the molecule, and the dashed line represents a single or double bond..

[0255] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form a structure selected from

[0256] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form.

[0257] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form a structure selected fromny-2734555Docket No.: 79275-20026.40

[0258] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form.

[0259] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form a structure selected from

[0260] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, L and the ring bearing Z1-Z4together form a structure selected from

[0261] In some embodiments of the compound of formula (B), or a pharmaceutically acceptable salt of any of the foregoing, the compound is of formula (B-X): ny-2734555Docket No.: 79275-20026.40Ra, Rb, and Rcare each independently H; or any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis C1-6alkyl; n is 1; Rmis C1-6alkyl; R2is H, or -OH; and X3, and X4are, independently of each other, H, halo, or -CN; provided that at least one of X3, and X4is halo, or -CN.

[0262] It is to be understood that any variation or embodiment of R1, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, Rn, Rx, Ry, Rz, X1, X2, X3, X4, Z1, Z2, Z3, Z4, L, Y, m, n, p, q, r, s, and t provided herein can be combined with every other variation or embodiment of R1, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rm, Rn, Rx, Ry, Rz, X1, X2, X3, X4, Z1, Z2, Z3, Z4, L, Y, m, n, p, q, r, s, and t provided, the same as if each and every combination had been individually and specifically described.

[0263] In some embodiments of the compound of formula (B), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, the compound is a compound of FIG.2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. 140 ny-2734555Docket No.: 79275-20026.40

[0264] In some embodiments, the compound of formula (B) is selected from the group consisting of: 3-(2-(2-methyl-4-(((5-(methylsulfonyl)pyrazin-2-yl)oxy)methyl)pyrrolidin-1- yl)ethyl)benzonitrile; 1-[5-chloro-2,3-dihydro-1H-inden-2-yl]-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidine; 1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidine; 3-chloro-6-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-1-carbonitrile; 3-chloro-5-[2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]propyl]benzonitrile; 3-chloro-5-{2-[4-{[(5-methanesulfonylpyridin-2-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; 3-chloro-5-[2-[3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propyl]benzonitrile; 3-{2-[3-{[(5-methanesulfonylpyrazin-2-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; [1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-3-yl]methanol; 5-chloro-3-{2-[3-(hydroxymethyl)-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-1- yl]ethyl}-2-methylbenzonitrile; 3-chloro-5-{2-[3-(hydroxymethyl)-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[3-(hydroxymethyl)-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[4-{[(6-methanesulfonylpyridazin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 7-[4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 141ny-2734555Docket No.: 79275-20026.40 3-{2-[4-{[(6-methanesulfonyl-5-methylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 7-[4-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 7-[4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 7-[2-methyl-4-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]- 5,6,7,8-tetrahydronaphthalene-2-carbonitrile; 5-{2-[4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzene- 1,3-dicarbonitrile; 6-[4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-1-carbonitrile; 3-chloro-6-[4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1- yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; 3-chloro-6-[4-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1- yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; 1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-{[4-(2- methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidine; 1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidine; 3-chloro-6-[4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-1-carbonitrile; 7-[4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 2-(4-{[1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-5-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethan-1-ol; 3-{2-[4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 142ny-2734555Docket No.: 79275-20026.40 N-[2-(4-{[1-[2-(3-chloro-5-cyanophenyl)ethyl]-5-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethyl]-N-methylacetamide; N-[2-(4-{[1-[2-(3-cyanophenyl)ethyl]-5-methylpyrrolidin-3-yl]methoxy}benzenesulfonyl)ethyl]- N-methylacetamide; 3-{2-[3-[(4-{[(2-methanesulfonylethyl)imino](methyl)oxo-λ⁶-sulfanyl}phenoxy)methyl]-4- methylpyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[3-methyl-4-[({6-[methyl(methylimino)oxo-λ⁶-sulfanyl]pyridin-3- yl}oxy)methyl]pyrrolidin-1-yl]ethyl}benzonitrile; 5-{2-[3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzene- 1,3-dicarbonitrile; N-[2-(4-{[1-[2-(3-chloro-5-cyanophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethyl]-N-methylacetamide; N-[2-(4-{[1-[2-(3-cyanophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}benzenesulfonyl)ethyl]- N-methylacetamide; 3-chloro-5-{2-[3-{[4-(1-methanesulfonylcyclopropyl)phenoxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[3-{[4-(3-methanesulfonyloxetan-3-yl)phenoxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; methyl 4-(4-{[1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)butanoate; methyl 4-(4-{[1-[2-(3-chloro-5-cyanophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)butanoate; 3-{2-[3-[(3,5-difluoro-4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[3-[(3,5-difluoro-4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[3-[(4-methanesulfonyl-3-methylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[3-[(4-methanesulfonyl-3-methylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile;ny-2734555Docket No.: 79275-20026.40 3-chloro-5-{2-[3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 5-{[1-[2-(3-cyanophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}-2- methanesulfonylbenzonitrile; 3-{2-[3-{[(6-methanesulfonyl-5-methylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 1-(5-chloro-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidine; 3-chloro-5-{2-[3-({4-[(1,1-dioxo-1λ⁶-thietan-3-yl)methanesulfonyl]phenoxy}methyl)-4- methylpyrrolidin-1-yl]ethyl}benzonitrile; 7-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 3-[1-hydroxy-2-[4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl]benzonitrile; 3-[1-hydroxy-2-[4-{[(6-methanesulfonyl-5-methylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin- 1-yl]ethyl]benzonitrile; 3-chloro-5-[1-hydroxy-2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]propyl]benzonitrile; 3-chloro-5-(1-hydroxy-2-(3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1- yl)propyl)benzonitrile; 3-{1-hydroxy-2-[3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-[1-hydroxy-2-[3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl]benzonitrile; 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonyloxetan-3-yl)phenoxy]methyl}piperazine; 1-[2-(3-chlorophenyl)ethyl]-3-({4-[(1-methylazetidin-3-yl)sulfonyl]phenoxy}methyl)piperazine; 1-[3-(4-{[4-[2-(3-chlorophenyl)ethyl]piperazin-2-yl]methoxy}benzenesulfonyl)azetidin-1- yl]ethan-1-one; 3-chloro-5-{2-[3-{[4-(1-methanesulfonylcyclopropyl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 144ny-2734555Docket No.: 79275-20026.40 3-chloro-5-{2-[3-{[4-(3-methanesulfonyloxetan-3-yl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[3-[(4-methanesulfonyl-3-methylphenoxy)methyl]piperazin-1- yl]ethyl}benzonitrile; 3-{2-[3-{[4-methanesulfonyl-3-(trifluoromethyl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[3-{[4-methanesulfonyl-3-(trifluoromethyl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 3-(3-chlorophenyl)-2-[3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan- 1-ol; 3-(3-chlorophenyl)-2-[3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]propan-1-ol; 3-chloro-5-[3-hydroxy-2-[3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propyl]benzonitrile; [1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-2-yl]methanol; 3-{[2-[(4-methanesulfonylphenoxy)methyl]-octahydroindolizin-5-yl]methyl}-5- chlorobenzonitrile; 3-chloro-5-(1-hydroxy-3-(3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1- yl)propan-2-yl)benzonitrile; 3-chloro-5-[1-hydroxy-3-[3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propan-2-yl]benzonitrile; 3-chloro-5-[1-hydroxy-3-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]propan-2-yl]benzonitrile; 1-(7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl)-3-[(4- methanesulfonylphenoxy)methyl]piperidine; 1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(4- methanesulfonylphenoxy)methyl]piperidine; 6-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-1-carbonitrile; 7-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile;ny-2734555Docket No.: 79275-20026.40 1-[5-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidine; and 1-[2-(3-chlorophenyl)ethyl]-3-{[4-(1-methanesulfonylethyl)phenoxy]methyl}piperazine; and or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Isotopically labeled forms of any of the foregoing are also embraced, such as deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein. Mixtures of any of the foregoing are also embraced and described. Prodrugs of any of the foregoing are also embraced herein.

[0265] In some embodiments, the compound of formula (B) is selected from the group consisting of: 3-(2-((2R,4S)-2-methyl-4-(((5-(methylsulfonyl)pyrazin-2-yl)oxy)methyl)pyrrolidin-1- yl)ethyl)benzonitrile; (2R,4S)-1-[5-chloro-2,3-dihydro-1H-inden-2-yl]-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidine; (2R,4S)-1-[(2R)-5-chloro-2,3-dihydro-1H-inden-2-yl]-4-[(4-methanesulfonylphenoxy)methyl]- 2-methylpyrrolidine; (2R,4S)-1-[(2S)-5-chloro-2,3-dihydro-1H-inden-2-yl]-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidine; (2R,4S)-1-[(2S)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(4- methanesulfonylphenoxy)methyl]-2-methylpyrrolidine; (2R,4S)-1-[(2R)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(4- methanesulfonylphenoxy)methyl]-2-methylpyrrolidine; 3-chloro-6-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-1-carbonitrile; (6S)-3-chloro-6-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]- 5,6,7,8-tetrahydronaphthalene-1-carbonitrile; (6R)-3-chloro-6-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]- 5,6,7,8-tetrahydronaphthalene-1-carbonitrile; 3-chloro-5-[( 2R)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]propyl]benzonitrile; 146ny-2734555Docket No.: 79275-20026.40 3-chloro-5-[( 2S)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1- yl]propyl]benzonitrile; 3-chloro-5-{2-[(2R,4S)-4-{[(5-methanesulfonylpyridin-2-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; (3S,4S)-1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(4-methanesulfonylphenoxy)methyl]- 4-methylpyrrolidine; (3S,4S)-1-[(2S)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(4- methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; (3S,4S)-1-[(2R)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(4- methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; 3-chloro-5-[2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propyl]benzonitrile; 3-chloro-5-[(2S)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propyl]benzonitrile; 3-chloro-5-[(2R)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propyl]benzonitrile; 3-{2-[(3S,4S)-3-{[(5-methanesulfonylpyrazin-2-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; [(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-3- yl]methanol; [(3R,4R)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-3- yl]methanol; 5-chloro-3-{2-[(3S,4S)-3-(hydroxymethyl)-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-1- yl]ethyl}-2-methylbenzonitrile; 3-chloro-5-{2-[(3S,4S)-3-(hydroxymethyl)-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-(hydroxymethyl)-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-1- yl]ethyl}benzonitrile; 3-{2-[(2R,4S)-4-{[(6-methanesulfonylpyridazin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile;ny-2734555Docket No.: 79275-20026.40 7-[(2R,4S)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 7-[(2R,4S)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 7-[(2R,4S)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 3-{2-[(2R,4S)-4-{[(6-methanesulfonyl-5-methylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 7-[(2R,4S)-4-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]- 5,6,7,8-tetrahydronaphthalene-2-carbonitrile; 7-[(2R,4S)-4-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]- 5,6,7,8-tetrahydronaphthalene-2-carbonitrile; 7S)-7-[(2R,4S)-4-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin- 1-yl]-5,6,7,8-tetrahydronaphthalene-2-carbonitrile; (7R)-7-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-2-carbonitrile; 7-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1- yl]-5,6,7,8-tetrahydronaphthalene-2-carbonitrile; (7S)-7-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-2-carbonitrile; (7R)-7-[(2R,4S)-2-methyl-4-({4-[methyl(methylimino)oxo-λ⁶- sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-2-carbonitrile; (7S)-7-[(2R,4S)-2-methyl-4-({4-[methyl(methylimino)oxo-λ⁶- sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-2-carbonitrile; 5-{2-[(2R,4S)-4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzene-1,3-dicarbonitrile; 6-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1- yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; (6S)-6-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; 148ny-2734555Docket No.: 79275-20026.40 (6R)-6-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; 3-chloro-6-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; (6R)-3-chloro-6-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; (6S)-3-chloro-6-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; 3-chloro-6-[(2R,4S)-4-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; (6S)-3-chloro-6-[(2R,4S)-4-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; (6R)-3-chloro-6-[(2R,4S)-4-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; (2R,4S)-1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-{[4-(2- methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidine; (2R,4S)-1-[(2S)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-{[4-(2- methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidine; (2R,4S)-1-[(2R)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-{[4-(2- methanesulfonylethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidine; (2R,4S)-1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidine; (2R,4S)-1-[(2R)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidine; (2R,4S)-1-[(2S)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-{[4-(3- methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidine; 3-chloro-6-[(2R,4S)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1- yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; (6R)-3-chloro-6-[(2R,4S)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2- methylpyrrolidin-1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; 149ny-2734555Docket No.: 79275-20026.40 (6S)-3-chloro-6-[(2R,4S)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin- 1-yl]-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; 7-[(2R,4S)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; (7R)-7-[(2R,4S)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]- 5,6,7,8-tetrahydronaphthalene-2-carbonitrile; (7S)-7-[(2R,4S)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]- 5,6,7,8-tetrahydronaphthalene-2-carbonitrile; 2-(4-{[(3S,5R)-1-[7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-5-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethan-1-ol; 2-(4-{[(3S,5R)-1-[(2R or 2S)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-5-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethan-1-ol; 2-(4-{[(3S,5R)-1-[(2S or 2R)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-5-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethan-1-ol; 3-{2-[(2R,4S)-4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(2R,4S)-4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2-methylpyrrolidin-1- yl]ethyl}benzonitrile; N-[2-(4-{[(3S,5R)-1-[2-(3-chloro-5-cyanophenyl)ethyl]-5-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethyl]-N-methylacetamide; N-[2-(4-{[(3S,5R)-1-[2-(3-cyanophenyl)ethyl]-5-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethyl]-N-methylacetamide; 3-{2-[(3S,4S)-3-[(4-{[(2-methanesulfonylethyl)imino](methyl)oxo-λ⁶- sulfanyl}phenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-[(4-{[(2-methanesulfonylethyl)imino](methyl)oxo-λ⁶- sulfanyl}phenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-[(4-{[(2-methanesulfonylethyl)imino](methyl)oxo-λ⁶- sulfanyl}phenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-methyl-4-[({6-[methyl(methylimino)oxo-λ⁶-sulfanyl]pyridin-3- yl}oxy)methyl]pyrrolidin-1-yl]ethyl}benzonitrile;ny-2734555Docket No.: 79275-20026.40 3-{2-[(3S,4S)-3-methyl-4-[({6-[methyl(methylimino)oxo-λ⁶-sulfanyl]pyridin-3- yl}oxy)methyl]pyrrolidin-1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-methyl-4-[({6-[methyl(methylimino)oxo-λ⁶-sulfanyl]pyridin-3- yl}oxy)methyl]pyrrolidin-1-yl]ethyl}benzonitrile; 5-{2-[(3S,4S)-3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzene-1,3-dicarbonitrile; N-[2-(4-{[(3S,4S)-1-[2-(3-chloro-5-cyanophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethyl]-N-methylacetamide; N-[2-(4-{[(3S,4S)-1-[2-(3-cyanophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)ethyl]-N-methylacetamide; 3-chloro-5-{2-[(3S,4S)-3-{[4-(1-methanesulfonylcyclopropyl)phenoxy]methyl}-4- methylpyrrolidin-1-yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S,4S)-3-{[4-(3-methanesulfonyloxetan-3-yl)phenoxy]methyl}-4- methylpyrrolidin-1-yl]ethyl}benzonitrile; methyl 4-(4-{[(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)butanoate; methyl 4-(4-{[(3S,4S)-1-[2-(3-chloro-5-cyanophenyl)ethyl]-4-methylpyrrolidin-3- yl]methoxy}benzenesulfonyl)butanoate; 3-{2-[(3S,4S)-3-[(3,5-difluoro-4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S,4S)-3-[(3,5-difluoro-4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin- 1-yl]ethyl}benzonitrile; 3-{2-[(3S,4S)-3-[(4-methanesulfonyl-3-methylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S,4S)-3-[(4-methanesulfonyl-3-methylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S,4S)-3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; 5-{[(3S,4S)-1-[2-(3-cyanophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}-2- methanesulfonylbenzonitrile;ny-2734555Docket No.: 79275-20026.40 3-{2-[(3S,4S)-3-{[(6-methanesulfonyl-5-methylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin-1- yl]ethyl}benzonitrile; (2R,4S)-1-(5-chloro-1,2,3,4-tetrahydronaphthalen-2-yl)-4-[(4-methanesulfonylphenoxy)methyl]- 2-methylpyrrolidine; 3-chloro-5-{2-[(3S,4S)-3-({4-[(1,1-dioxo-1λ⁶-thietan-3-yl)methanesulfonyl]phenoxy}methyl)-4- methylpyrrolidin-1-yl]ethyl}benzonitrile; 7-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; 3-[(1R)-1-hydroxy-2-[(2R,4S)-4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2- methylpyrrolidin-1-yl]ethyl]benzonitrile; 3-[(1S)-1-hydroxy-2-[(2R,4S)-4-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-2- methylpyrrolidin-1-yl]ethyl]benzonitrile; 3-[(1R)-1-hydroxy-2-[(2R,4S)-4-{[(6-methanesulfonyl-5-methylpyridin-3-yl)oxy]methyl}-2- methylpyrrolidin-1-yl]ethyl]benzonitrile; 3-[(1S)-1-hydroxy-2-[(2R,4S)-4-{[(6-methanesulfonyl-5-methylpyridin-3-yl)oxy]methyl}-2- methylpyrrolidin-1-yl]ethyl]benzonitrile; 3-chloro-5-[(1S,2S)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidin-1-yl]propyl]benzonitrile; 3-chloro-5-[( 1S,2R)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidin-1-yl]propyl]benzonitrile; 3-chloro-5-[( 1S,2S)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidin-1-yl]propyl]benzonitrile; 3-chloro-5-[( 1R,2R)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidin-1-yl]propyl]benzonitrile; 3-chloro-5-((1R,2S)-1-hydroxy-2-((3S,4S)-3-methyl-4-((4- (methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)propyl)benzonitrile; 3-chloro-5-((1S,2R)-1-hydroxy-2-((3S,4S)-3-methyl-4-((4- (methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)propyl)benzonitrile; 3-chloro-5-((1R,2R)-1-hydroxy-2-((3S,4S)-3-methyl-4-((4- (methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)propyl)benzonitrile;ny-2734555Docket No.: 79275-20026.40 3-chloro-5-((1S,2S)-1-hydroxy-2-((3S,4S)-3-methyl-4-((4- (methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)propyl)benzonitrile; 3-{1-hydroxy-2-[(3S,4S)-3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4-methylpyrrolidin- 1-yl]ethyl}benzonitrile; 3-[(1S)-1-hydroxy-2-[(3S,4S)-3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4- methylpyrrolidin-1-yl]ethyl]benzonitrile; 3-[(1R)-1-hydroxy-2-[(3S,4S)-3-{[(6-methanesulfonylpyridin-3-yl)oxy]methyl}-4- methylpyrrolidin-1-yl]ethyl]benzonitrile; (3S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonyloxetan-3- yl)phenoxy]methyl}piperazine; (3S)-1-[2-(3-chlorophenyl)ethyl]-3-({4-[(1-methylazetidin-3- yl)sulfonyl]phenoxy}methyl)piperazine; 1-[3-(4-{[(2S)-4-[2-(3-chlorophenyl)ethyl]piperazin-2-yl]methoxy}benzenesulfonyl)azetidin-1- yl]ethan-1-one; 3-chloro-5-{2-[(3S)-3-{[4-(1-methanesulfonylcyclopropyl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S)-3-{[4-(3-methanesulfonyloxetan-3-yl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S)-3-[(4-methanesulfonyl-3-methylphenoxy)methyl]piperazin-1- yl]ethyl}benzonitrile; 3-{2-[(3S)-3-{[4-methanesulfonyl-3-(trifluoromethyl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 3-chloro-5-{2-[(3S)-3-{[4-methanesulfonyl-3-(trifluoromethyl)phenoxy]methyl}piperazin-1- yl]ethyl}benzonitrile; 3-(3-chlorophenyl)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propan-1-ol; (2R)-3-(3-chlorophenyl)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin- 1-yl]propan-1-ol; (2S)-3-(3-chlorophenyl)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin- 1-yl]propan-1-ol;ny-2734555Docket No.: 79275-20026.40 (2R)-3-(3-chlorophenyl)-2-[(3S)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]propan- 1-ol; (2S)-3-(3-chlorophenyl)-2-[(3S)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]propan- 1-ol; 3-chloro-5-[3-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]propyl]benzonitrile; 3-chloro-5-[(2R)-3-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidin-1-yl]propyl]benzonitrile; 3-chloro-5-[(2S)-3-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidin-1-yl]propyl]benzonitrile; [(2S,4S)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-2- yl]methanol; [(2S,4R)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]pyrrolidin-2- yl]methanol; 3-{[(2S,5R)-2-[(4-methanesulfonylphenoxy)methyl]-octahydroindolizin-5-yl]methyl}-5- chlorobenzonitrile; 3-{[(2R,5S)-2-[(4-methanesulfonylphenoxy)methyl]-octahydroindolizin-5-yl]methyl}-5- chlorobenzonitrile; 3-{[(2R,5R)-2-[(4-methanesulfonylphenoxy)methyl]-octahydroindolizin-5-yl]methyl}-5- chlorobenzonitrile; 3-{[(2S,5S)-2-[(4-methanesulfonylphenoxy)methyl]-octahydroindolizin-5-yl]methyl}-5- chlorobenzonitrile; 3-chloro-5-(1-hydroxy-3-((3S,4S)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1- yl)propan-2-yl)benzonitrile; 3-chloro-5-[(2R)-1-hydroxy-3-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidin-1-yl]propan-2-yl]benzonitrile; 3-chloro-5-[(2S)-1-hydroxy-3-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidin-1-yl]propan-2-yl]benzonitrile; 3-chloro-5-[(2R)-1-hydroxy-3-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidin-1-yl]propan-2-yl]benzonitrile;ny-2734555Docket No.: 79275-20026.40 3-chloro-5-[(2S)-1-hydroxy-3-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidin-1-yl]propan-2-yl]benzonitrile; (3R)-1-(7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl)-3-[(4- methanesulfonylphenoxy)methyl]piperidine; (3R)-1-[(2S)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(4- methanesulfonylphenoxy)methyl]piperidine; (3R)-1-[(2R)-7-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-3-[(4- methanesulfonylphenoxy)methyl]piperidine; (6R)-6-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-1-carbonitrile; (6S)-6-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-1-carbonitrile; (7S)-7-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; (7R)-7-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]-5,6,7,8- tetrahydronaphthalene-2-carbonitrile; (2R,4S)-1-[(2R)-5-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(4- methanesulfonylphenoxy)methyl]-2-methylpyrrolidine; (2R,4S)-1-[(2S)-5-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]-4-[(4- methanesulfonylphenoxy)methyl]-2-methylpyrrolidine; (3S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(1-methanesulfonylethyl)phenoxy]methyl}piperazine; (3S)-1-[2-(3-chlorophenyl)ethyl]-3-({4-[(1R)-1- methanesulfonylethyl]phenoxy}methyl)piperazine; and (3S)-1-[2-(3-chlorophenyl)ethyl]-3-({4-[(1S)-1- methanesulfonylethyl]phenoxy}methyl)piperazine; or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Isotopically labeled forms of any of the foregoing are also embraced, such as deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein. Mixtures of any of the foregoing are also embraced and described. Prodrugs of any of the foregoing are also embraced herein.ny-2734555Docket No.: 79275-20026.40

[0266] In some embodiments, a compound of formula (B-X) is selected from the group consisting of: 3-chloro-5-{2-[3-methyl-4-({4-[(3-methyloxetan-3-yl)sulfonyl]phenoxy}methyl)pyrrolidin-1- yl]ethyl}benzonitrile; 1-(3-chlorophenyl)-2-[trans-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethan-1-ol; 1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine; 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidine; 1-(3-chlorophenyl)-2-[trans-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1- yl]ethan-1-ol; and 1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidine or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Isotopically labeled forms of any of the foregoing are also embraced, such as deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein. Mixtures of any of the foregoing are also embraced and described. Prodrugs of any of the foregoing are also embraced herein.

[0267] In some embodiments, a compound of formula (B), such as a compound of formula (B- X), is selected from the group consisting of: 3-chloro-5-{2-[(3S,4S)-3-methyl-4-({4-[(3-methyloxetan-3- yl)sulfonyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile; (1R) or (1S)-1-(3-chlorophenyl)-2-[trans-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidin-1-yl]ethan-1-ol; (3R,4R)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidine; (2S,4S)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidine; (1S) or (1R)-1-(3-chlorophenyl)-2-[trans-3-[(4-methanesulfonylphenoxy)methyl]-4- methylpyrrolidin-1-yl]ethan-1-ol; and (2R,4R)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2- methylpyrrolidineny-2734555Docket No.: 79275-20026.40 or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Isotopically labeled forms of any of the foregoing are also embraced, such as deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein. Mixtures of any of the foregoing are also embraced and described. Prodrugs of any of the foregoing are also embraced herein.

[0268] Compound Names included in FIG.1 and FIG.2 and in the lists in the paragraphs above were generated using ChemDraw®software version 18.1.0.458 or Collaborative Drug Discovery Inc. (CDD) CDD Vault update #3.

[0269] In some embodiments, the compounds provided herein inhibit APOL1 at a concentration of less than 10 μM, less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein inhibit APOL1 at a concentration of 1 to 10 μM, 0.01 to 1 μM, or 0.01 to 10 μM.

[0270] In some embodiments, the compounds provided herein reduce cell death caused by overexpression of APOL1. In some embodiments, the compounds provided herein reduce cell death caused by overexpression APOL1 at a concentration of less than 10 μM, less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein reduce cell death caused by APOL1 overexpression at a concentration of 1 to 10 μM, 0.01 to 1 μM, or 0.01 to 10 μM.

[0271] In some embodiments, compounds provided herein have an EC50of less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein have an EC50of 1 to 10 μM, 0.01 to 1 μM, or 0.01 to 10 μM.

[0272] In some embodiments, compounds provided herein have an AC50of less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein have an AC50of 1 to 10 μM, 0.01 to 1 μM, or 0.01 to 10 μM. In some embodiments, the AC50value reflects the compound’s ability to prevent calcium influx by inhibiting APOL1.

[0273] In some embodiments, the compounds provided herein inhibit a cation channel. In some embodiments, the compounds of the present disclosure inhibit a calcium channel. In some embodiments, the compounds of the present disclosure reduce calcium transport.

[0274] In some embodiments, the individual has a gain-of-function mutation in APOL1. In some embodiments, the individual has an APOL1 risk allele. In some embodiments, the APOL1ny-2734555Docket No.: 79275-20026.40 risk allele is a missense variant. In some embodiments, the APOL1 risk allele is a G0 variant. In some embodiments, the G0 variant is G0 E150 (p.K150E). COMPOSITIONS

[0275] Provided herein are pharmaceutical compositions comprising one or more compounds of formula (A) or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, provided herein is a pharmaceutical composition comprising (i) of formula (A) or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0276] Suitable pharmaceutically acceptable excipients may include, for example, fillers, diluents, sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizers, and adjuvants. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression / encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending / gelling agent, or wet granulation agent. Examples of suitable excipients are well-known to those skilled in the art. Such compositions are prepared in a manner well known in the pharmaceutical art. See, e.g., Handbook of Pharmaceutical Excipients, Pharmaceutical Press, 9thed. (2020), and Remington’s Pharmaceutical Sciences, Academic Press, 23rded. (2020), each of which is incorporated herein by reference in its entirety.

[0277] The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical composition may be administered by various methods including, for example, oral, rectal, buccal, intranasal, and transdermal routes. In certain embodiments, the pharmaceutical composition may be administered by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant. In some embodiments, the administration is oral administration.

[0278] Compounds as described herein may be administered to individuals in a form of generally accepted oral compositions, such as tablets, coated tablets, gel capsules in a hard or in soft shell, emulsions or suspensions. Examples of carriers, which may be used for the preparation of suchny-2734555Docket No.: 79275-20026.40 compositions, are lactose, corn starch or its derivatives, talc, stearate or its salts, etc. Acceptable carriers for gel capsules with soft shell are, for instance, plant oils, wax, fats, semisolid and liquid poly-ols, and so on. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants.

[0279] The specific dose level of a compound as described herein will depend upon a variety of factors such as the age, body weight and sex of the individual as well as the route of administration and other factors. In some embodiments, a dosage is expressed as a number of milligrams of a compound described herein per kilogram of the individual’s body weight (mg / kg). Dosages of between about 0.1 mg / kg and 100-150 mg / kg may be appropriate.

[0280] The compound may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, which in some variations may be for the duration of the individual’s life. KITS

[0281] The present disclosure further provides kits for carrying out the methods of the invention. The kits may comprise a compound or pharmaceutically acceptable salt thereof as described herein and suitable packaging. The kits may comprise one or more containers comprising any compound described herein. In one aspect, a kit includes a compound of the disclosure or a pharmaceutically acceptable salt thereof, and a label and / or instructions for use of the compound in the treatment of a disease or disorder described herein. The kits may comprise a unit dosage form of the compound.

[0282] Provided herein are kits, comprising (i) a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating diabetic retinopathy in an individual in need thereof. Also provided herein are kits, comprising (i) a pharmaceutical composition comprising a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for useny-2734555Docket No.: 79275-20026.40 in treating diabetic retinopathy in an individual in need thereof. In some embodiments, the diabetic retinopathy is selected from the group consisting of non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema. In some embodiments, the administration comprises oral administration or intravitreal injection. In some embodiments, the administration comprises oral administration. In some embodiments, the administration comprises intravitreal injection. In some embodiments, the method further comprises administration of an anti-VEGF agent, an Angiopoietin 2 blocking agent, a dual VEGF-Angiopoietin 2 blocking agent, a corticosteroid, or laser therapy to the subject.

[0283] Provided herein are kits, comprising (i) a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in preventing and / or delaying the development of diabetic retinopathy in an individual in need thereof. Also provided herein are kits, comprising (i) a pharmaceutical composition comprising a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use in preventing and / or delaying the development of diabetic retinopathy in an individual in need thereof. Provided herein are kits, comprising (i) a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in delaying the development of diabetic retinopathy in an individual in need thereof. Also provided herein are kits, comprising (i) a pharmaceutical composition comprising a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use in delaying the development of diabetic retinopathy in an individual in need thereof. In some embodiments, the diabetic retinopathy is selected from the group consisting of non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema. In some embodiments, the administration comprises oral administration or intravitreal 160ny-2734555Docket No.: 79275-20026.40 injection. In some embodiments, the administration comprises oral administration. In some embodiments, the administration comprises intravitreal injection. In some embodiments, the method further comprises administration of an anti-VEGF agent, an Angiopoietin 2 blocking agent, a dual VEGF-Angiopoietin 2 blocking agent, a corticosteroid, or laser therapy to the subject.

[0284] Articles of manufacture are also provided, wherein the article of manufacture comprises a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in a suitable container. Also provided herein are articles of manufacture, comprising a pharmaceutical composition comprising a compound of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, or intravenous bag. EXAMPLES

[0285] The following synthetic reaction schemes, which are detailed in the Schemes, General Procedures, and Examples, are merely illustrative of some of the methods by which the compounds of the present disclosure, or an embodiment or aspect thereof, can be synthesized. Various modifications to these synthetic reaction schemes can be made, as will be apparent to those of ordinary skill in the art.

[0286] The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.

[0287] Although certain exemplary embodiments are depicted and described herein, the compounds of the present disclosure, or any variation or embodiment thereof, may be prepared using appropriate starting materials according to the methods described generally herein and / or by methods available to one of ordinary skill in the art. Synthetic Examples 161ny-2734555Docket No.: 79275-20026.40

[0288] As depicted in the Schemes, General Procedures, and Examples below, in certain exemplary embodiments, compounds of formula (A), or formula (B), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, are prepared according to the general procedures. The general methods below, and other methods known to synthetic chemists of ordinary skill in the art, can be applied to all formulae, variations, embodiments, and species described herein. Scheme A-1

[0289] Compounds of formulae A-S7 to A-S9 may be prepared by the general synthetic method shown in Scheme A-1. It is to be understood that, where applicable, the moieties and variables depicted in Scheme A-1 are as defined elsewhere herein for a compound of formula (A), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In addition, with reference to Scheme A-1, m is an integer from 0-5 and q is an integer from 0-5, provided that 1 ≤ (m + q) ≤ 6. 162ny-2734555Docket No.: 79275-20026.40

[0290] C–O bond formation may be accomplished through either a Mitsunobu reaction with phenols of formula A-S2 or an SNAr with aryl fluorides of formula A-S3 to provide compounds of formula A-S4. Deprotection of the N-tert-butyloxycarbonyl (Boc) group may proceed using a protic acid such as hydrochloric acid to give compounds of formula A-S5. Compounds of formula A-S7 can be prepared through reductive amination using an aldehyde of formula A-S6 and a hydride source such as NaBH3CN. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formulas A-S8 and A-S9. Scheme A-2

[0291] Compounds of formulas A-S7 to A-S9 may be prepared by the alternative general synthetic method shown in Scheme A-2. It is to be understood that, where applicable, the moieties and variables depicted in Scheme A-2 are as defined elsewhere herein for a compound of formula (A), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In addition, with reference to Scheme A-2: m is an integer from 0-5 and q is an integer from 0-5, provided that 1 ≤ (m + q) ≤ 6; and Z1is halo (for example: chloro or bromo) or a sulfonate ester (for example: mesylate).ny-2734555Docket No.: 79275-20026.40

[0292] C–O coupling of an aryl halide of formula A-S10 with an alcohol of formula A-S1 may be performed using conditions such as copper(I) iodide, Cs2CO3, and 3,4,7,8-tetramethyl-1,10- phenanthroline in toluene at an elevated temperature to afford compounds of formula A-S4. Deprotection of the N-tert-butyloxycarbonyl (Boc) group may proceed using a protic acid such as trifluoroacetic acid to give compounds of formula S5. Compounds of formula S7 can be prepared using a base such as K2CO3, an alkyl halide or alkyl sulfonate ester such as alkyl bromide of formula A-S11, and an organic solvent such as MeCN at elevated temperature. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formulas A-S8 and A-S9. Scheme A-3

[0293] Compounds of formulas A-S7 to A-S9 may be prepared by the alternative general synthetic method shown in Scheme A-3. It is to be understood that, where applicable, the moieties and variables depicted in Scheme A-3 are as defined elsewhere herein for a compound of formula (A), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In addition, with reference to 164ny-2734555Docket No.: 79275-20026.40 Scheme A-3: m is an integer from 0-5 and q is an integer from 0-5, provided that 1 ≤ (m + q) ≤ 6; and Z2is halo (for example: chloro or bromo) or a sulfonate ester (for example: mesylate).

[0294] C–O bond formation may be accomplished through an SN2 reaction with alkyl halide or alkyl sulfonate ester such as alkyl bromide of formula A-S12 with phenols of formula A-S2 in the presence of bases such as K2CO3to give compounds of formula A-S4. Deprotection of the N- tert-butyloxycarbonyl (Boc) group may proceed using a protic acid such as HCl to give compounds of formula A-S5. Compounds of formula A-S7 can be prepared through reductive amination using an aldehyde of formula A-S6 and a hydride source such as NaBH3CN. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formula A-S8 and A-S9. Scheme A-4

[0295] Compounds of formula A-S17 may be prepared by the alternative general synthetic method shown in Scheme A-4. It is to be understood that, where applicable, the moieties and variables depicted in Scheme A-4 are as defined elsewhere herein for a compound of formula (A), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0296] Compounds of formula A-S17 with (S)-stereochemistry may be accessed by treating phenols of formula A-S2 with (R)-2-(chloromethyl)oxirane (S13) in the presence of a phase transfer catalyst such as TBAB and a base such as NaOH. Alternately, treatment of phenol A-S2 with (R)-oxiran-2-ylmethanol A-S14 and Mitsunobu conditions such as PPh3and DIAD may also provide (S)-A-S15. Epoxide opening to provide compounds of formula A-S17 proceeds in the presence of amines of formula A-S16, triethylamine in cases where the salt form of amine A- S16 is used, as a solution in ethanol at elevated temperatures. In cases where epimeric –OHny-2734555Docket No.: 79275-20026.40 stereochemistry of compounds of formula A-S17 is desired, the above synthetic scheme may be modified to utilize (S)-2-(chloromethyl)oxirane or (S)-oxiran-2-ylmethanol. Scheme A-5.

[0297] Compounds of formula A-S24 may be prepared according to Scheme A-5. Reductive amination of a mono-protected piperazine such as A-S18 with an aldehyde such as A-S6 gives compound A-S19. Removal of the the N-tert-butyloxycarbonyl (Boc) group upon treatment with a protic acid such as HCl in a solvent such as MeOH gives A-S20. Treatment with thionyl chloride, triethylamine, and imidazole gives rise to A-S21. Oxidation to the oxathiazolidine-2,2- dioxide occurs on treatment with ruthenium (III) chloride and sodium periodate in a mixed solvent system of acetonitrile and water to give A-S22. Heating A-S22 with a phenol such as A- S23 and potassium carbonate in DMF, followed by treatment with aqueous HCl, gives compounds of formula A-S24. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula A-S24. Scheme A-6. 166ny-2734555Docket No.: 79275-20026.40

[0298] An alternative synthetic approach to compounds of formula A-S24 is depicted in Scheme A-6. Reaction of piperazine A-S18 with benzyl chloroformate in the presence of a base such as sodium bicarbonate generates the bis-carbamate A-S25. Mitsunobu coupling of phenol A-S23 with triphenylphosphine and DIAD in THF generates A-S26. Selective cleavage of the benzyl carbamate may be achieved by treatment with thionyl chloride, triethylamine, and imidazole in DCM to give A-S27, which may then undergo reductive amination using sodium triacetoxyborohydride provides compounds of formula A-S28. Cleavage of the the N-tert- butyloxycarbonyl (Boc) group provides A-S24. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula A- S24.ny-2734555Docket No.: 79275-20026.40 Scheme A-7.

[0299] Scheme A-7 outlines an approach to compounds of formula A-S32. Addition of an alkylzinc reagent generated in situ from benzyl bromide A-S29 to an iminium ion formed by reaction of piperazine A-S27 and aldehyde A-S30 gives A-S31. Removal of the N-tert- butyloxycarbonyl (Boc) group using a protic acid such as HCl in a solvent such as MeOH gives A-S32. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula A-S32. Scheme A-8.

[0300] A synthetic approach to compounds of formula A-S28 is depicted in Scheme A-8. Selective removal of the benzyl carbamate of A-S26 via hydrogenation gives piperazine A-S27. 168ny-2734555Docket No.: 79275-20026.40 Reductive amination under the action of sodium triacetoxyborohydride generates A-S34. Further manipulation may be accomplished by Suzuki coupling with a boronic acid (X1B(OH2)), Pd(dppf)Cl2catalyst, and potassium carbonate to give A-S24. Removal of the N-tert- butyloxycarbonyl (Boc) group upon reaction with HCl in EtOAc gives compounds of formula A- S28. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula A-S28.

[0301] Scheme A-9 depicts an alternate application of the three-component coupling described in Scheme A-7. Coupling of pyrrolidine A-S35, benzyl bromide A-S29, and formaldehyde provides compounds of formula A-S36. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formula A-S37. Scheme A-10. 169ny-2734555Docket No.: 79275-20026.40

[0302] Scheme A-10 depicts an alternative approach to pyrrolidine analogs of formula A-S48. NaBH4reduction of β-keto ester A-S40 gives diol A-S41, which can undergo SNAr reaction with fluorobenzene A-S42 upon heating in DMF with potassium carbonate as base. Oxidation to ketone A-S44 may be achieved with the Dess-Martin periodinane. Reaction with an alkyl metal reagent such as methylmagnesium bromide gives tertiary alcohol A-S45, as a mixture of isomers. Removal of the N-tert-butyloxycarbonyl (Boc) group with a protic acid such as TFA, followed by reductive amination with aldehyde A-S6, gives pyrrolidine A-S47. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formula A-S48. Scheme A-11.ny-2734555Docket No.: 79275-20026.40

[0303] Scheme A-11 depicts a route to analogs bearing substituted piperazine cores. Reductive amination of piperazine A-S49 and aldehyde A-S6 with 2-methyl pyridine borane complex gives A-S50. Reduction of the carboxylic acid A-S50 with borane-dimethylsulfide gives alcohol A- S51, which may undergo SNAr reaction with fluorobenzene A-S42 to give A-S52. Removal of the N-tert-butyloxycarbonyl (Boc) group with a protic acid such as HCl in a solvent such as MeOH gives piperazine A-S53. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formula A-S54. Scheme A-12.

[0304] Scheme A-12 depicts an approach to compounds of formula A-S57. Amide bond formation between an amine such as pyrrolidine A-S55 and carboxylic acid A-S6 using EDC andny-2734555Docket No.: 79275-20026.40 HOBt with a tertiary amine base such as DIEA to provide A-S56. Amide reduction can be achieved upon treatment with lithium aluminum hydride to give compounds of formula A-S57. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula A-S57. General Procedure for Intermediate A-1

[0305] To a solution of 4-methoxy-N-methyl-aniline (G1, 7.00 g, 51.0 mmol) in DCM (60 mL) was added TEA (14.2 mL, 102 mmol). After cooling the reaction to 0 °C, MsCl (5.13 mL, 66.3 mmol) was added dropwise. The mixture was stirred at room temperature for 1 h. The reaction mixture was cooled to 0 °C and quenched by the addition of water (40 mL). The biphasic mixture was extracted with DCM (60 mL x 2). The combined organic layers were washed with brine (40 mL), dried over Na2SO4, filtered and concentrated in vacuo to give N-(4- methoxyphenyl)-N-methylmethanesulfonamide (G2), which was used in the next step without further purification. MS = 216.1 [M+H]+.

[0306] To a –78 °C solution of N-(4-methoxyphenyl)-N-methylmethanesulfonamide (G2, 11.4 g, 53.0 mmol) in DCM (100 mL) was added BBr3(10.2 mL, 106 mmol) dropwise. The mixture was warmed to 0 °C and stirred for 2 h. The reaction mixture was quenched by the dropwise addition of water (70 mL), and the mixture was stirred at room temperature for 20 min. Then the mixture was extracted with DCM (100 mL x 3). The combined organic layers were washed with brine (80 mL), dried over Na2SO4, filtered and concentrated under in vacuo to give N-(4- hydroxyphenyl)-N-methyl-methanesulfonamide (G3). MS = 202.2 [M+H]+.

[0307] To a solution of N-(4-hydroxyphenyl)-N-methyl-methanesulfonamide (G3, 4.00 g, 19.9 mmol) and (R)-2-(chloromethyl)oxirane (G4, 3.12 mL, 39.8 mmol) in water (10 mL) and THF (20 mL) was added TBAB (897 mg, 2.78 mmol). Next, a solution of NaOH (1.19 g, 29.8 mmol) in water (10 mL) was added dropwise. The mixture was stirred at room temperature for 12 h. The reaction mixture was diluted by the dropwise addition of water (20 mL), and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by normal phaseny-2734555Docket No.: 79275-20026.40 silica gel chromatography (Biotage 40 g cartridge, 0–55% EtOAc in petroleum ether). The resulting residue was further purified by re-crystallization (50 mL of 1:10 EtOAc in petroleum ether) to give (S)-N-methyl-N-(4-(oxiran-2-ylmethoxy)phenyl)methanesulfonamide (Intermediate A-1). MS = 280.0 [M+Na]+.

[0308] The following intermediates in Table A-2 were prepared according to procedures similar to those described for Intermediate A-1 using the appropriate starting materials. Table A-2General Procedure for Intermediate A-7ny-2734555Docket No.: 79275-20026.40

[0309] To a solution of tert-butyl (R)-3-(hydroxymethyl)piperidine-1-carboxylate (G6, 1.00 g, 4.64 mmol) and 4-methylsulfonylphenol (G5, 800 mg, 4.64 mmol) in THF (20 mL) was added PPh3(2.44 g, 9.29 mmol). The mixture was cooled to 0 °C and DIAD (1.88 g, 9.29 mmol, 1.81 mL, 2.00 eq) was added dropwise. After stirring at room temperature for 12 h, the reaction mixture was concentrated in vacuo. The residue was purified by normal phase silica gel chromatography (Biotage 12 g cartridge, 1–25% EtOAc in petroleum ether) to give (tert-butyl (R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate (G7). MS = 387.2 [M+NH4]+.

[0310] To a solution of (tert-butyl (R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1- carboxylate (7, 780 mg, 2.11 mmol, 1.00 eq) in EtOAc (5 mL) was added HCl / EtOAc (4 M, 10 mL). The mixture was stirred at room temperature for 2 h. The suspension was triturated with MTBE (100 mL) and the resulting solid was isolated through filtration to give (R)-3-((4- (methylsulfonyl)phenoxy)methyl)piperidine (Intermediate A-7) which was used in the next step without further purification. MS = 270.1 [M+H]+.

[0311] The following intermediate in Table A-3 was prepared according to procedures similar to those described for Intermediate A-7 using the appropriate starting materials. Table A-3General Procedure for Intermediate A-9ny-2734555Docket No.: 79275-20026.40

[0312] To a solution of 3-bromo-2-methyl-benzonitrile (G8, 5.00 g, 25.5 mmol) and 4,4,5,5- tetramethyl-1,3,2-dioxaborolane (32.6 g, 255 mmol) in THF (80 mL) under N2was added 4-tert- butyl-2-(4-tert-butyl-2-pyridyl)pyridine (685 mg, 2.55 mmol) and [Ir(cod)(OMe)]2(845 mg, 1.28 mmol). Then the mixture was stirred at 80 °C for 8 h under N2. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO 80 g cartridge, 0– 20% EtOAc:Hexane) to give 3-bromo-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzonitrile (G9).1H NMR (400 MHz, CDCl3): δ 8.15 (s, 1H), 7.98 (s, 1H), 2.65 (s, 3H), 1.35 (s, 12H).

[0313] To solution of 3-bromo-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzonitrile (G9, 3.10 g, 9.63 mmol) in MeOH (30 mL) and H2O (10 mL) was added CuCl2(3.88 g, 28.9 mmol) at room temperature, then the mixture was stirred at 90 °C for 16 h. After cooling to room temperature, the reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–5% EtOAc:Hexane) to give 3-bromo-5-chloro-2-methyl-benzonitrile (G10).1H NMR (400 MHz, CDCl3): δ 7.78 (s, 1H), 7.57 (s, 1H), 2.61 (s, 3H).

[0314] To a solution of 3-bromo-5-chloro-2-methyl-benzonitrile (G10, 300 mg, 1.30 mmol) and 2-[(E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (296 mg, 1.50 mmol) in 1,4- dioxane (5 mL) under N2were added K2CO3(360 mg, 2.60 mmol) and Pd(dppf)Cl2(95.2 mg, 130 μmol). Then the mixture was stirred at 80 °C for 16 h. The reaction mixture was allowed to 175ny-2734555Docket No.: 79275-20026.40 cool to room temperature, diluted with H2O (10 mL), and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 4 g cartridge, 0–5% EtOAc:Hexane) to give 5-chloro-3-[(E)-2- ethoxyvinyl]-2-methyl-benzonitrile (G11). MS = 222.1 [M+H]+.

[0315] To a solution of 5-chloro-3-[(E)-2-ethoxyvinyl]-2-methyl-benzonitrile (G11, 1.50 g, 6.77 mmol) in THF (12 mL) was added aqueous HCl (4 M, 12 mL), and then the mixture was stirred at 50 °C for 5 h. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0–50% EtOAc:Hexane) to give 5-chloro- 2-methyl-3-(2-oxoethyl)benzonitrile (Intermediate A-9). MS = 194.0 [M+H]+. General Procedure for Intermediate A-10

[0316] To a solution of 4-sulfanylphenol (G12, 4.75 g, 37.7 mmol) and 1- methylsulfonylethylene (4 g, 37.7 mmol) in DMF (40 mL) was added K2CO3(7.81 g, 56.5 mmol). The mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with H2O (100 mL) and then extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 40 g cartridge, 0–40% EtOAc:Hexane) to give 4-((2-(methylsulfonyl) ethyl) thio) phenol (G13). MS = 231.1 [M–H]–.

[0317] To a solution of 4-(2-methylsulfonylethylsulfanyl) phenol (G13, 3.00 g, 12.9 mmol) in THF (40 mL) at room temperature was added a mixture of NaIO4(5.50 g, 25.8 mmol) in H2O (10 mL). The mixture was then stirred at 40 °C for 16 h. The reaction mixture was diluted with saturated aqueous Na2SO3(20 mL), extracted with EtOAc (20 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified byny-2734555Docket No.: 79275-20026.40 flash silica gel chromatography (ISCO 40 g cartridge, 0–100% EtOAc:Hexane) to give 4-(2- methylsulfonylethylsulfonyl) phenol (Intermediate A-10). MS = 263.1 [M–H]–. General Procedure for Intermediate A-11

[0318] To a suspension of NaH (73 mg, 1.83 mmol, 60% by weight in mineral oil) in THF (5 mL) was added a solution of trimethylsulfonium iodide (374 mg, 1.83 mmol) in DMSO (3 mL) under N2. After 10 min, a solution of 3-formylbenzonitrile (G14, 200 mg, 1.53 mmol) in THF (2 mL) was slowly added. The reaction mixture was degassed and purged with N2for 3 times, and then the mixture was stirred at room temperature for 12 h under N2. The reaction mixture was quenched by addition of H2O (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 4 g cartridge, 0–50% EtOAc:Hexane) to give 3-(oxiran-2- yl)benzonitrile (Intermediate A-11). MS = 146.1 [M+H]+. General Procedure for Intermediate A-12

[0319] A mixture of 4-sulfanylphenol (G12, 1 g, 7.93 mmol,), 1-bromo-2-methoxy-ethane (1.10 g, 7.93 mmol) and Cs2CO3 (2.58 g, 7.93 mmol) in DMF (12 mL) was stirred at 60°C for 3 h. The reaction mixture was poured into ice water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 20 g cartridge, 0–20% EtOAc:Hexane) to give 4-(2- methoxyethylsulfanyl)phenol (G18). MS = 183.1 [M–H]–.ny-2734555Docket No.: 79275-20026.40

[0320] A mixture of 4-(2-methoxyethylsulfanyl)phenol (G18, 700 mg, 3.80 mmol) and NaIO4(2.44 g, 11.4 mmol) in THF (6 mL) and H2O (6 mL) was stirred at 70 °C for 16 h. The mixture was filtered, quenched with saturated aqueous Na2S2O3(15 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (40 mL), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 20 g cartridge, 0–70% EtOAc:Hexane) to give 4-(2- methoxyethylsulfonyl)phenol (Intermediate A-12). MS = 217.1 [M+H]+.

[0321] The following intermediate in Table A-4 was prepared according to procedures similar to those described for Intermediate A-12 using the appropriate starting materials. Table A-4General Procedure for Intermediate A-14 and Intermediate A-15

[0322] To a solution of tert-butyl 3-bromoazetidine-1-carboxylate (1.87 g, 7.93 mmol) in DMF (30 mL) at room temperature were added Cs2CO3(5.16 g, 15.85 mmol) and 4-sulfanylphenol (G12, 1.00 g, 7.93 mmol), and the resulting mixture was stirred at 90 °C for 16 h. The reaction mixture was poured into water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0-100% EtOAc:hexane) to give tert-butyl 3-(4- hydroxyphenyl)sulfanylazetidine-1-carboxylate (G19). MS = 282.1 [M+H]+. 178ny-2734555Docket No.: 79275-20026.40

[0323] To a solution of tert-butyl 3-(4-hydroxyphenyl)sulfanylazetidine-1-carboxylate (G19, 50 mg, 178 μmol) in DCM (2 mL) at 0 °C was added m-CPBA (46 mg, 267 μmol, 77% purity) at 0 °C. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched by addition saturated aqueous Na2SO3(5 mL), and then extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (5 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by by flash silica gel chromatography (Biotage 4 g cartridge, 0–50% EtOAc:Hexane) to give tert-butyl 3-(4- hydroxyphenyl)sulfonylazetidine-1-carboxylate (Intermediate A-14). MS = 258.0 [M– C4H8+H]+.

[0324] To a solution of tert-butyl 3-(4-hydroxyphenyl)sulfonylazetidine-1-carboxylate (Intermediate A-14, 0.5 g, 1.91 mmol) in MeOH (3 mL) was added HCl / MeOH (4 M, 3 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then concentrated under reduced pressure to give 4-(azetidin-3-ylsulfonyl)phenol HCl salt (G20), which was taken to the next step without further purification. MS = 214.1 [M+H]+.

[0325] To a solution of 4-(179zetidine-3-ylsulfonyl)phenol (G20, 400 mg, 1.60 mmol, HCl salt) in MeOH (5 mL) and AcOH (0.05 mL) were added HCHO (120 mg, 4.00 mmol) and borane-2- methylpyridine complex (205 mg, 1.90 mmol). The mixture was stirred at 40 °C for 16 h. The reaction mixture was quenched by addition of saturated aqueous NaHCO3(10 mL), and then extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0–100% EtOAc:Hexane) to give 4-(1-methylazetidin-3-yl)sulfonylphenol (Intermediate A-15). MS = 228.0 [M+H]+. General Procedure for Intermediate A-16

[0326] To a solution of methyl 5-chloro-2-hydroxy-benzoate (G21, 2.00 g, 10.7 mmol) in DMF (20 mL) were added K2CO3(2.96 g, 21.4 mmol) and CH3I (7.61 g, 53.6 mmol). The mixture was stirred at 40 °C for 16 h. The reaction mixture was then cooled to room temperature, poured intony-2734555Docket No.: 79275-20026.40 water (100 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (80 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the residue, which was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–10% EtOAc:Hexane) to give methyl 5-chloro-2-methoxy-benzoate (G22). MS = 201.0 [M+H]+.

[0327] To a solution of methyl 5-chloro-2-methoxy-benzoate (G22, 1.50 g, 7.48 mmol) in THF (15 mL) was added LiBH4(2 M in THF, 7.5 mL, 15.0 mmol) at 0°C. The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, filtered and concentrated to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–50% EtOAc:Hexane) to give (5-chloro-2-methoxy- phenyl)methanol (G23).1H NMR (400 MHz, CDCl3): δ 7.30 (d, J = 2.8 Hz, 1H), 7.25 – 7.21 (m, 1H), 6.81 (d, J = 8.8 Hz, 1H), 4.66 (s, 2H), 3.86 (s, 3H).

[0328] To a solution of (5-chloro-2-methoxy-phenyl)methanol (G23, 1.10 g, 6.37 mmol) in DCM (50 mL) at 0 °C was added PBr3(1.73 g, 6.37 mmol). The reaction mixture was then stirred at room temperature for 16 h. The mixture was concentrated, diluted with water (50 mL) and neutralized by addition of saturated aqueous NaHCO3to pH=7-8, then extracted with DCM (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated to give 2-(bromomethyl)-4-chloro-1-methoxy-benzene (Intermediate A-16).1H NMR (400 MHz, CDCl3): δ 7.27 (d, J = 2.8 Hz, 1H), 7.21 (dd, J = 5.6 Hz, 2.8 Hz, 1H), 6.77 (d, J = 8.8 Hz, 1H), 4.45 (s, 2H), 3.85 (s, 3H). General Procedure for Intermediate A-17

[0329] To a mixture of methyl 5-chloro-2-hydroxy-benzoate (G24, 1.50 g, 8.04 mmol,) in MeCN (75 mL) and H2O (37.5 mL) were added KOH (2.71 g, 48.2 mmol) and [bromo(difluoro)methyl]-trimethylsilane (3.27 g, 16.1 mmol) at 0 °C. The mixture was then stirred at room temperature for 16 h. The reaction mixture was poured into water (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (25 180ny-2734555Docket No.: 79275-20026.40 mL), dried over Na2SO4, filtered and concentrated under reduced presure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–20% EtOAc:Hexane) to give methyl 5-chloro-2-(difluoromethoxy)benzoate (G25).1H NMR (400 MHz, DMSO-d6): δ 7.86 (d, J = 2.8 Hz, 1H), 7.75 (dd, J = 8.8 Hz, 2.8 Hz, 1H), 7.37 (d, J = 9.2 Hz, 1H), 7.20 (t, J = 73.6 Hz, 1H), 7.21 – 7.03 (m, 1H), 3.85 (s, 3H).

[0330] To a mixture of methyl 5-chloro-2-(difluoromethoxy)benzoate (G25, 200 mg, 845 μmol) in THF (5 mL) at 0 °C was added LiBH4(4 M in THF, 634 μL, 2.54 mmol) dropwise under N2, the mixture was then stirred at room temperature for 16 h under N2. The reaction mixture was poured into saturated aqueous NH4Cl (5 mL), then extracted with EtOAc (15 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give [5-chloro-2-(difluoromethoxy)phenyl]methanol (G26), which was used without further purification. MS = 190.9 [M–H2O+H]+.

[0331] To a solution of [5-chloro-2-(difluoromethoxy)phenyl]methanol (G26, 170 mg, 815 μmol) in DCM (3 mL) was added PBr3(221 mg, 815 μmol) at 0 °C. The mixture was stirred at room temperature for 1 h. The reaction mixture was then poured into water (15 mL) and extracted with DCM (10 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 4g cartridge, 0–10% EtOAc:Hexane) to give 2-(bromomethyl)-4-chloro-1-(difluoromethoxy)benzene (Intermediate A-17).1H NMR (400 MHz, DMSO-d6): δ 7.69 (d, J = 2.4 Hz, 1H), 7.50 (dd, J = 8.0 Hz, 2.8 Hz, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.31 (t, J = 73.2 Hz, 1H), 4.63 (s, 2H). General Procedure for Intermediate A-18

[0332] To a mixture of 2-(3,5-dichlorophenyl)ethanol (G27, 1.00 g, 5.23 mmol) in DCM (10 mL) was added DMP (2.66 g, 6.28 mmol). The mixture was then stirred at room temperature for 3 h under N2. The reaction mixture was diluted with H2O (5 mL) and extracted with EtOAc (8 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified byny-2734555Docket No.: 79275-20026.40 flash silica gel chromatography (Biotage 12 g cartridge, 0–20% EtOAc:Hexane) to give 2-(3, 5- dichlorophenyl) acetaldehyde (Intermediate A-18).1H NMR (400 MHz, DMSO-d6): δ 9.68 (s, 1H), 7.53 (s, 1H), 7.47 (s, 1H), 7.46 (s, 1H), 3.86 (s, 2H).

[0333] The following intermediate in Table A-5 was prepared according to procedures similar to those described for Intermediate A-18 using the appropriate starting materials. Table A-5General Procedure for Intermediate A-21

[0334] To a solution of 2-[(E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (503 mg, 2.54 mmol) and 3-bromo-5-chloro-benzonitrile (G28, 500 mg, 2.31 mmol) in dioxane (10 mL) were added K2CO3(958 mg, 6.93 mmol) and Pd(dppf)Cl2(169 mg, 231 μmol) under N2. The reaction mixture was then stirred at 100 °C for 16 h under N2. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give (E)-3-chloro-5-(2-ethoxyvinyl)benzonitrile (G29), which was taken to the next step without further purification.1H NMR (400 MHz, CDCl3): δ 7.40 (s, 1H), 7.36 (s, 1H), 7.35 (s, 1H), 7.05 (d, J = 13.2 Hz, 1H), 5.73 (d, J = 12.8 Hz, 1H), 3.94 (q, J = 7.2 Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H).

[0335] To a solution of (E)-3-chloro-5-(2-ethoxyvinyl)benzonitrile (G29, 750 mg, 3.61 mmol) in THF (4 mL) was added HCl (3 M in H2O, 4 mL). The reaction mixture was then stirred at 50 °Cny-2734555Docket No.: 79275-20026.40 for 16 h. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 4 g cartridge, 0–30% EtOAc:Hexane) to give 3-chloro-5-(2- oxoethyl)benzonitrile (Intermediate A-21).1H NMR (400 MHz, CDCl3): δ 9.81 (s, 1H), 7.60 (s, 1H), 7.46 (s, 1H), 7.42 (s, 1H), 3.80 (s, 2H).

[0336] The following intermediate in Table A-6 was prepared according to procedures similar to those described for Intermediate A-21 using the appropriate starting materials. Table A-6General Procedure for Intermediate A-23

[0337] To a solution of 3-bromo-5-chloro-benzonitrile (G28, 2.50 g, 11.5 mmol), potassium vinyltrifluoroborate (3.09 g, 23.1 mmol) in dioxane (25 mL) and H2O (2.5 mL) were added K2CO3(3.19 g, 23.1 mmol) and Pd(dppf)Cl2(845 mg, 1.15 mmol). The mixture was purged with N2three times and then stirred at 80 °C for 16 h. The reaction mixture was poured into water (50 mL) and extracted with EtOAc (40 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (BIOTAGE 20 g cartridge, 0–10% EtOAc:Hexane) to give 3-chloro-5-vinyl-benzonitrile (G30).1H NMR (400 MHz, CDCl3): δ 7.60 (s, 1H), 7.56 (s, 1H), 7.52 (s, 1H), 6.69 – 6.62 (m, 1H), 5.85 (d, J = 17.6 Hz, 1H), 5.47 (d, J = 10.8 Hz, 1H).

[0338] To a solution of 3-chloro-5-vinyl-benzonitrile (G30, 500 mg, 3.06 mmol) in DCM (5 mL) was added mCPBA (931 mg, 4.58 mmol, 85% purity) at 0 °C, the reaction was stirred at roomny-2734555Docket No.: 79275-20026.40 temperature for 16 h. The reaction mixture was then poured into saturated aqueous Na2SO3(20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (120 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0– 100% EtOAc:Hexane) to give 3-chloro-5-(oxiran-2-yl)benzonitrile (Intermediate A-23).The following intermediate in Table A-7 was prepared according to procedures similar to those described for Intermediate A-23 using the appropriate starting materials. Table A-7General Procedure for Intermediate A-25

[0339] A mixture of 3-methyl-5-(trifluoromethyl) benzonitrile (G31, 750 mg, 4.05 mmol), NBS (865 mg, 4.86 mmol) and AIBN (67 mg, 405 μmol) in DCE (7.5 mL) was stirred at 90 °C for 6 h. The mixture was then diluted with DCM (20 mL) and washed with water (20 mL). The organic layer was concentrated under reduced presure. The residue was purified twice by flash silica gel chromatography (Biotage 12 g cartridge, 0–1% EtOAc:Hexane) to give 3- (bromomethyl)-5-(trifluoro methyl)benzonitrile (Intermediate A-25). MS = 264.0 / 266.1 [M+H]+. General Procedure for Intermediate A-26ny-2734555Docket No.: 79275-20026.40

[0340] To a mixture of 4-sulfanylphenol (G12, 2.00 g, 15.8 mmol) and methyl 2-bromo-2- methyl-propanoate (2.40 g, 13.3 mmol) in DMF (30 mL) was added Cs2CO3(7.20 g, 22.1 mmol). The mixture was then stirred at 80 °C for 16 h. The reaction mixture was diluted with saturated aqueous NH4Cl (30 mL), extracted with EtOAc (30 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0–100% EtOAc:Hexane) to give methyl 2- (4-hydroxyphenyl) sulfanyl-2-methyl-propanoate (G32). MS = 225.2 [M-H]-.

[0341] To a solution of methyl 2-(4-hydroxyphenyl) sulfanyl-2-methyl-propanoate (G32, 2.30 g, 10.2 mmol) in THF (30 mL) was added a solution of NaIO4(6.52 g, 30.5 mmol) in H2O (6 mL). The mixture was stirred at 50 °C for 16 h. The reaction mixture was quenched with saturated aqueous Na2SO3(15 mL), extracted with EtOAc (10 mL x 3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–30% EtOAc:Hexane) to give methyl 2-(4- hydroxyphenyl) sulfonyl-2-methyl-propanoate (G33). MS = 257.1 [M–H]–.

[0342] To a solution of methyl 2-(4-hydroxyphenyl) sulfonyl-2-methyl-propanoate (G33, 2.30 g, 8.90 mmol) in THF (30 mL) at 0 °C was added LiAlH4(507 mg, 13.4 mmol). The mixture was stirred at room temperature for 2 h. The residue was diluted with aqueous NaOH (5 M, 2 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 4 g cartridge, 0–100% EtOAc:Hexane to give 4-(2-hydroxy-1, 1-dimethyl-ethyl) sulfonylphenol (Intermediate A-26). MS = 229.0 [M–H]–. General Procedure for Intermediate A-27ny-2734555Docket No.: 79275-20026.40

[0343] To a solution of 4-sulfanylphenol (G12, 10.0 g, 79.2 mmol) in DMF (100 mL) were added K2CO3(10.9 g, 79.2 mmol) and tert-butyl 3-iodoazetidine-1-carboxylate (22.4 g, 79.2 mmol). The mixture was then stirred at 40 °C for 16 h. The reaction mixture was diluted with water (200 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with H2O (80 mL) and brine (80 mL), dried over (Na2SO4), filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with MTBE (100 mL) at room temperature for 5 h and filtered to give tert-butyl 3-(4-hydroxyphenyl)sulfanylazetidine- 1-carboxylate (G19). MS = 226.1 [M–C4H8+H]+.

[0344] To a solution of tert-butyl 3-(4-hydroxyphenyl) sulfanylazetidine-1-carboxylate (G19, 6.50 g, 13.9 mmol) in THF (60 mL) and H2O (20 mL) was added NaIO4(8.80 g, 41.6 mmol, ). The mixture was stirred at 50 °C for 16 h. The reaction mixture was cooled to room temperature, quenched with saturated aqueous Na2SO3(60 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–100% EtOAc:Hexane ) to give tert-butyl 3- (4- hydroxyphenyl) sulfonylazetidine-1-carboxylate (Intermediate A-14). MS = 312.2 [M–H]–.

[0345] To a solution of tert-butyl 3-(4-hydroxyphenyl) sulfonylazetidine-1-carboxylate (Intermediate A-14, 1.5 g, 4.79 mmol) in MeOH (4 mL) was added HCl / MeOH (4 M, 12 mL). The mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure to give 4-(azetidin-3-ylsulfonyl) phenol HCl salt (G20), which was used without further purification. MS = 214.1 [M+H]+.

[0346] To a solution of 4-(azetidin-3-ylsulfonyl)phenol (G20, 1.1 g, 4.41 mmol, HCl salt) in DCM (10 mL) were added TEA (1.11 g, 11.0 mmol, 1.53 mL) and allyl chloroformate (584 mg, 4.85 mmol) at 0 °C. The mixture was then stirred at room temperature for 3 h. The reaction mixture was diluted with H2O (30 mL) and extracted with DCM (15 mL x 3). The combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0–100% EtOAc:Hexane) to give allyl 3-(4- hydroxyphenyl)sulfonylazetidine-1-carboxylate (Intermediate A-27). MS = 298.1 [M+H]+. General Procedure for Intermediate A-28ny-2734555Docket No.: 79275-20026.40

[0347] To a solution of 3-chloro-5-(hydroxymethyl)benzonitrile (G34, 500 mg, 2.98 mmol) in DCM (10 mL) was added PBr3 (807 mg, 2.98 mmol) at 0 °C. The reaction mixture was then stirred at room temperature for 10 h, then the reaction mixture was concentrated. The residue was diluted with water (10 mL) and neutralized by addition of saturated aqueous NaHCO3to pH = 7, then extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered and concentrated to give 3-(bromomethyl)-5-chloro- benzonitrile (Intermediate A-28), which was taken to the next step without further purification.1H NMR (400 MHz, CDCl3): δ 7.63 (s, 1H), 7.58 (s, 2H), 4.43 (s, 2H). General Procedure for Intermediate A-29

[0348] To a solution of 3-methylsulfonylpropan-1-ol (G35, 500 mg, 3.62 mmol) in DCM (5 mL) at 0 °C were added Et3N (732 mg, 7.24 mmol) and methylsulfonyl methanesulfonate (945 mg, 5.43 mmol). The mixture was stirred at 0 °C for 2 h. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give crude 3-(methylsulfonyl)propyl methanesulfonate (G36), which was taken to the next step without further purification.1H NMR (400 MHz, DMSO-d6): δ 4.30 (t, J = 6.4 Hz, 2H), 3.23 – 3.01 (m, 5H), 3.01 (s, 3H), 2.13 – 2.08 (m, 2H).

[0349] To a mixture of 3-(methylsulfonyl)propyl methanesulfonate (G36, 390 mg, 1.80 mmol) and 4-sulfanylphenol (G12, 318 mg, 2.52 mmol) in CH3CN (5 mL) was added Cs2CO3(705 mg, 2.16 mmol). The mixture was then stirred at room temperature for 2 h. The reaction mixture wasny-2...

Claims

Docket No.: 79275-20026.40 CLAIMS What is claimed is:

1. A method of treating diabetic retinopathy in a subject in need thereof, comprising administering to the subject an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

2. The method of claim 1, wherein the diabetic retinopathy is selected from the group consisting of non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema.

3. The method of claims 1 or 2, wherein the APOL1 inhibitor is a compound of formula (A) or (B):or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: when the compound is a compound of formula A, Q is absent or is -N-(C1-6alkyl); Y is O or -N-(C1-6alkyl), provided that, when Q is -N(C1-6alkyl), then Y is O; Ra, Rb, and Rcare each independently H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2- C1-6alkyl,ny-2734555 398Docket No.: 79275-20026.40 or any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl; L is selected from the group consisting of: (i), wherein A is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rxis H, or Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0- 6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy; R1and R2are independently H, halo, or -OH, or one of R1and R2is taken together with Rx, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0- 6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, and the other of R1and R2is H, halo, or - OH; R3is H, -OH, halo, or C1-6alkoxy; and R4and R5are independently H, or R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl,ny-2734555 399Docket No.: 79275-20026.40 provided that either: (1) Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C1-6alkyl, or C1-6alkoxy, or (2) R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl; (ii), wherein E is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); p is 0 or 1, provided that, when p is 1, then E is O; R6is H or -OH; Ryis H, or Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R7is H, or R7is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R8and R9are independently H or C1-6alkyl,ny-2734555 400Docket No.: 79275-20026.40 or one of R8and R9is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R8and R9is H or C1-6alkyl, or one of R8and R9is taken together with R10, and the atoms to which they are attached, to form a C3-8cycloalkyl, and the other of R8and R9is H or C1-6alkyl; and R10is H, or R10is taken together with one of R8and R9, and the atoms to which they are attached, to form a C3-8cycloalkyl, provided that: (1) Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (2) Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (3) one of R8and R9is taken together with R10and the atoms to which they are attached, to form a C3-8cycloalkyl; and (iii), wherein G is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rzis H or C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more C3-8cycloalkyl; R11and R12are independently H, -OH, halo, or C1-6alkyl; and R13and R14are independently H, C1-6alkyl, or C3-8cycloalkyl, or R13and R14are taken, together with the atoms to which they are attached, to form a 3- 8 membered heterocyclyl,ny-2734555 401Docket No.: 79275-20026.40 wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X1- X4; and X1, X2, X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, provided that at least one of X1, X2, X3, and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and when the compound is a compound of Formula (B), m is 0 or 1; Y is O or -N(C1-6alkyl), wherein the C1-6alkyl is optionally substituted with one or more Rgsubstituents; Z1, Z2, Z3, and Z4are, independently of each other, -N-, -CH- or -C(Rf)-; Ra, Rb, and Rcare each independently H, C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents, or any two of Ra, Rb, and Rcare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is optionally substituted with one or more Risubstituents, and the other of Ra, Rb, and Rcis H or C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein,ny-2734555 402Docket No.: 79275-20026.40 the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents; Rdand Reare each independently H or C1-6alkyl, or Rdand Reare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-6 membered heterocycle; Rfis, independently at each occurrence, -CN, halo, C1-6alkyl, C1-6alkoxy, or -N(Rj)2, wherein the C1-6alkyl of Rfis optionally substituted with one or more halo; Rgis, independently at each occurrence, -S(O)2C1-6alkyl; Rhis, independently at each occurrence, -OH, C1-6alkoxy, -N(Rj)2, C(O)Rk, or - S(O)2C1-6alkyl; Riis, independently at each occurrence, oxo, C1-6alkyl, or C(O)Rk; Rjis independently at each occurrence H, C1-6alkyl or C(O)C1-6alkyl; Rkis, independently at each occurrence C1-6alkyl or C1-6alkoxy; L is selected from the group consisting of:, wherein Rxand R1are taken together with the atoms to which they are attached to form a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-ny-2734555 403Docket No.: 79275-20026.40 6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; R2is H, -OH, or C1-6alkyl, wherein the C1-6alkyl of R2is optionally substituted with one or more OH; and R3is H or C1-6alkyl, wherein the C1-6alkyl of R3is optionally substituted with one or more OH; provided that when L is (i), either: (1) m is 1, (2) at least one of Z1, Z2, Z3, and Z4is -N- or -C(Rf)-, (3) R3is other than H, (4) at least one of Ra, Rb, and Rcis heterocycle, or (5) at least one of Rg, Ri, Rj, Rk, and Rnis present; (ii), wherein Ry, R4, and R5are taken together with the atoms to which they are attached to form a 8- 20 membered bicyclic heterocycle, wherein the 8-20 membered bicyclic heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0- 6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; or (iii), wherein Rzand R6are taken together with the atoms to which they are attached to form a 3-8 membered heterocycleheterocycle substituted with n independently selected Rmny-2734555 404Docket No.: 79275-20026.40 substituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; and R7is taken, together with one of X1and X2and the atoms to which they are attached, to form a C4-8cycloalkyl; wherein, for each of (i)-(iii), # denotes the point of attachment to the ring bearing moieties moieties Z1-Z4and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4; X1, and X2are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, or one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, and the other of X1or X2is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.

4. The method of any of claims 1-3, wherein a therapeutically effective amount of the APOL1 inhibitor or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient is administered.

5. The method of any of claims 1-4, wherein the administration comprises oral administration or intravitreal injection.

6. The method of claim 5, wherein the administration comprises oral administration.

7. The method of claim 5, wherein the administration comprises intravitreal injection.ny-2734555 405Docket No.: 79275-20026.40 8. The method of any of claims 1-7, further comprising administration of an anti-VEGF agent, an Angiopoietin 2 blocking agent, a dual VEGF-Angiopoietin 2 blocking agent, a corticosteroid, or laser therapy to the subject.

9. The method of any of claims 1-8, wherein the compound of Formula (A) is a compound10. The method of any of claims 1-8, wherein the compound of Formula (B) is a compound of formulany-2734555 406Docket No.: 79275-20026.4011. A method of delaying the development of diabetic retinopathy in a subject in need thereof, comprising administering to the subject an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

12. The method of claim 11, wherein the diabetic retinopathy is selected from the group consisting of non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema.

13. The method of claims 11 or 12, wherein the APOL1 inhibitor is a compound of formula (A) or (B):or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: when the compound is a compound of formula A, Q is absent or is -N-(C1-6alkyl);ny-2734555 407Docket No.: 79275-20026.40 Y is O or -N-(C1-6alkyl), provided that, when Q is -N(C1-6alkyl), then Y is O; Ra, Rb, and Rcare each independently H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2- C1-6alkyl, or any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl; L is selected from the group consisting of:, wherein A is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rxis H, or Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0- 6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy; R1and R2are independently H, halo, or -OH, or one of R1and R2is taken together with Rx, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0- 6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, and the other of R1and R2is H, halo, or - OH;ny-2734555 408Docket No.: 79275-20026.40 R3is H, -OH, halo, or C1-6alkoxy; and R4and R5are independently H, or R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl, provided that either: (1) Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C1-6alkyl, or C1-6alkoxy, or (2) R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl; (ii)E is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); p is 0 or 1, provided that, when p is 1, then E is O; R6is H or -OH; Ryis H, or Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;ny-2734555 409Docket No.: 79275-20026.40 R7is H, or R7is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R8and R9are independently H or C1-6alkyl, or one of R8and R9is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R8and R9is H or C1-6alkyl, or one of R8and R9is taken together with R10, and the atoms to which they are attached, to form a C3-8cycloalkyl, and the other of R8and R9is H or C1-6alkyl; and R10is H, or R10is taken together with one of R8and R9, and the atoms to which they are attached, to form a C3-8cycloalkyl, provided that: (1) Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (2) Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (3) one of R8and R9is taken together with R10and the atoms to which they are attached, to form a C3-8cycloalkyl; and (iii), wherein G is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rzis H or C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more C3-8cycloalkyl; R11and R12are independently H, -OH, halo, or C1-6alkyl; andny-2734555 410Docket No.: 79275-20026.40 R13and R14are independently H, C1-6alkyl, or C3-8cycloalkyl, or R13and R14are taken, together with the atoms to which they are attached, to form a 3- 8 membered heterocyclyl, wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X1- X4; and X1, X2, X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, provided that at least one of X1, X2, X3, and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and when the compound is a compound of Formula (B), m is 0 or 1; Y is O or -N(C1-6alkyl), wherein the C1-6alkyl is optionally substituted with one or more Rgsubstituents; Z1, Z2, Z3, and Z4are, independently of each other, -N-, -CH- or -C(Rf)-; Ra, Rb, and Rcare each independently H, C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents,ny-2734555 411Docket No.: 79275-20026.40 or any two of Ra, Rb, and Rcare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is optionally substituted with one or more Risubstituents, and the other of Ra, Rb, and Rcis H or C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents; Rdand Reare each independently H or C1-6alkyl, or Rdand Reare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-6 membered heterocycle; Rfis, independently at each occurrence, -CN, halo, C1-6alkyl, C1-6alkoxy, or -N(Rj)2, wherein the C1-6alkyl of Rfis optionally substituted with one or more halo; Rgis, independently at each occurrence, -S(O)2C1-6alkyl; Rhis, independently at each occurrence, -OH, C1-6alkoxy, -N(Rj)2, C(O)Rk, or - S(O)2C1-6alkyl; Riis, independently at each occurrence, oxo, C1-6alkyl, or C(O)Rk; Rjis independently at each occurrence H, C1-6alkyl or C(O)C1-6alkyl; Rkis, independently at each occurrence C1-6alkyl or C1-6alkoxy; L is selected from the group consisting of:ny-2734555 412Docket No.: 79275-20026.40 Rxand R1are taken together with the atoms to which they are attached to form a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; R2is H, -OH, or C1-6alkyl, wherein the C1-6alkyl of R2is optionally substituted with one or more OH; and R3is H or C1-6alkyl, wherein the C1-6alkyl of R3is optionally substituted with one or more OH; provided that when L is (i), either: (1) m is 1, (2) at least one of Z1, Z2, Z3, and Z4is -N- or -C(Rf)-, (3) R3is other than H, (4) at least one of Ra, Rb, and Rcis heterocycle, or (5) at least one of Rg, Ri, Rj, Rk, and Rnis present; (ii)Ry, R4, and R5are taken together with the atoms to which they are attached to form a 8- 20 membered bicyclic heterocycle, wherein the 8-20 membered bicyclic heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0- 6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; orny-Docket No.: 79275-20026.40 Rzand R6are taken together with the atoms to which they are attached to form a 3-8 membered heterocycleheterocycle substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; and R7is taken, together with one of X1and X2and the atoms to which they are attached, to form a C4-8cycloalkyl; wherein, for each of (i)-(iii), # denotes the point of attachment to the ring bearing moieties moieties Z1-Z4and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4; X1, and X2are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, or one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, and the other of X1or X2is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.

14. The method of any of claims 11-13, wherein a therapeutically effective amount of the APOL1 inhibitor or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising an APOL1 inhibitor, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient is administered.

15. The method of any of claims 11-14, wherein the administration comprises oral administration or intravitreal injection.

16. The method of claim 14, wherein the administration comprises oral administration.

17. The method of claim 14, wherein the administration comprises intravitreal injection.ny-2734555 414Docket No.: 79275-20026.40 18. The method of any of claims 11-17, further comprising administration of an anti-VEGF agent, an Angiopoietin 2 blocking agent, a dual VEGF-Angiopoietin 2 blocking agent, a corticosteroid, or laser therapy to the subject.

19. The method of any of claims 11-18, wherein the compound of Formula (A) is a20. The method of any of claims 11-18, wherein the compound of Formula (B) is a compound of formulany-2734555 415Docket No.: 79275-20026.4021. A kit, comprising (i) an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and (ii) instructions for use in treating diabetic retinopathy in a subject in need thereof.

22. The kit of claim 21, wherein the diabetic retinopathy is selected from the group consisting of non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, vision threatening diabetic retinopathy, and diabetic macular edema.

23. The kit of claims 21 or 22, wherein the APOL1 inhibitor is a compound of formula (A) or (B):or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein: when the compound is a compound of formula A, Q is absent or is -N-(C1-6alkyl); Y is O or -N-(C1-6alkyl),ny-2734555 416Docket No.: 79275-20026.40 provided that, when Q is -N(C1-6alkyl), then Y is O; Ra, Rb, and Rcare each independently H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2- C1-6alkyl, or any two of Ra, Rb, and Rcare taken, together with the atoms to which they are attached, to form a C3-6cycloalkyl or a 3-6 membered heterocyclyl, and the other of Ra, Rb, and Rcis H or C1-6alkyl, wherein the C1-6alkyl of Ra, Rb, or Rcis independently optionally substituted with one or more -OH, C1-6alkoxy, or -S(O)2-C1-6alkyl; L is selected from the group consisting of: (i), wherein A is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rxis H, or Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0- 6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy; R1and R2are independently H, halo, or -OH, or one of R1and R2is taken together with Rx, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rgsubstituents, wherein n is an integer from 0- 6, and Rgis -OH, halo, C1-6alkyl, or C1-6alkoxy, and the other of R1and R2is H, halo, or - OH; R3is H, -OH, halo, or C1-6alkoxy; andny-2734555 417Docket No.: 79275-20026.40 R4and R5are independently H, or R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl, provided that either: (1) Rxis taken together with one of R1and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C1-6alkyl, or C1-6alkoxy, or (2) R4and R5are taken, together with the atoms to which they are attached, to form a C3-8cycloalkyl; (ii)E is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); p is 0 or 1, provided that, when p is 1, then E is O; R6is H or -OH; Ryis H, or Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R7is H,ny-2734555 418Docket No.: 79275-20026.40 or R7is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl; R8and R9are independently H or C1-6alkyl, or one of R8and R9is taken together with Ry, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R8and R9is H or C1-6alkyl, or one of R8and R9is taken together with R10, and the atoms to which they are attached, to form a C3-8cycloalkyl, and the other of R8and R9is H or C1-6alkyl; and R10is H, or R10is taken together with one of R8and R9, and the atoms to which they are attached, to form a C3-8cycloalkyl, provided that: (1) Ryis taken together with R7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (2) Ryis taken together with one of R8and R9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or (3) one of R8and R9is taken together with R10and the atoms to which they are attached, to form a C3-8cycloalkyl; and (iii), wherein G is O, NH, N(C1-6alkyl), CH2, or CH(C1-6alkyl); Rzis H or C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more C3-8cycloalkyl; R11and R12are independently H, -OH, halo, or C1-6alkyl; and R13and R14are independently H, C1-6alkyl, or C3-8cycloalkyl,ny-2734555 419Docket No.: 79275-20026.40 or R13and R14are taken, together with the atoms to which they are attached, to form a 3- 8 membered heterocyclyl, wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X1- X4; and X1, X2, X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, provided that at least one of X1, X2, X3, and X4is halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and when the compound is a compound of Formula (B), m is 0 or 1; Y is O or -N(C1-6alkyl), wherein the C1-6alkyl is optionally substituted with one or more Rgsubstituents; Z1, Z2, Z3, and Z4are, independently of each other, -N-, -CH- or -C(Rf)-; Ra, Rb, and Rcare each independently H, C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents, or any two of Ra, Rb, and Rcare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-8 membered heterocycle, wherein the 3-8 memberedny-2734555 420Docket No.: 79275-20026.40 heterocycle is optionally substituted with one or more Risubstituents, and the other of Ra, Rb, and Rcis H or C1-6alkyl, C3-6cycloalkyl, or 3-8 membered heterocycle wherein, the C1-6alkyl of Ra, Rb, or Rcis optionally substituted with one or more Rhsubstituents, and the 3-8 membered heterocycle of Ra, Rb, or Rcis optionally substituted with one or more Risubstituents; Rdand Reare each independently H or C1-6alkyl, or Rdand Reare taken together with the atoms to which they are attached to form a C3-6cycloalkyl or a 3-6 membered heterocycle; Rfis, independently at each occurrence, -CN, halo, C1-6alkyl, C1-6alkoxy, or -N(Rj)2, wherein the C1-6alkyl of Rfis optionally substituted with one or more halo; Rgis, independently at each occurrence, -S(O)2C1-6alkyl; Rhis, independently at each occurrence, -OH, C1-6alkoxy, -N(Rj)2, C(O)Rk, or - S(O)2C1-6alkyl; Riis, independently at each occurrence, oxo, C1-6alkyl, or C(O)Rk; Rjis independently at each occurrence H, C1-6alkyl or C(O)C1-6alkyl; Rkis, independently at each occurrence C1-6alkyl or C1-6alkoxy; L is selected from the group consisting of:, whereinny-2734555 421Docket No.: 79275-20026.40 Rxand R1are taken together with the atoms to which they are attached to form a 3-8 membered heterocycle, wherein the 3-8 membered heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; R2is H, -OH, or C1-6alkyl, wherein the C1-6alkyl of R2is optionally substituted with one or more OH; and R3is H or C1-6alkyl, wherein the C1-6alkyl of R3is optionally substituted with one or more OH; provided that when L is (i), either: (1) m is 1, (2) at least one of Z1, Z2, Z3, and Z4is -N- or -C(Rf)-, (3) R3is other than H, (4) at least one of Ra, Rb, and Rcis heterocycle, or (5) at least one of Rg, Ri, Rj, Rk, and Rnis present; (ii)Ry, R4, and R5are taken together with the atoms to which they are attached to form a 8- 20 membered bicyclic heterocycle, wherein the 8-20 membered bicyclic heterocycle is substituted with n independently selected Rmsubstituents, wherein n is an integer from 0- 6, and Rmis C1-6alkyl, or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; orny-Docket No.: 79275-20026.40 Rzand R6are taken together with the atoms to which they are attached to form a 3-8 membered heterocycleheterocycle substituted with n independently selected Rmsubstituents, wherein n is an integer from 0-6, and Rmis C1-6alkyl or C(O)C1-6alkyl, wherein the C1-6alkyl is optionally substituted with one or more Rnsubstituents, and Rnis, independently at each occurrence, -OH; and R7is taken, together with one of X1and X2and the atoms to which they are attached, to form a C4-8cycloalkyl; wherein, for each of (i)-(iii), # denotes the point of attachment to the ring bearing moieties moieties Z1-Z4and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4; X1, and X2are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo, or one of X1and X2is taken together with R7and the atoms to which it is attached to form a C4-8cycloalkyl, and the other of X1or X2is H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo; and X3, and X4are, independently of each other, H, halo, -CN, C1-6alkyl, C1-6alkoxy, or SF5, wherein the C1-6alkyl or C1-6alkoxy is optionally substituted with one or more halo.

24. The kit of any of claims 21-23, wherein the kit comprises a therapeutically effective amount of the APOL1 inhibitor or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising an APOL1 inhibitor or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

25. The kit of any of claims 21-24, wherein the administration comprises oral administration or intravitreal injection.

26. The kit of claim 25, wherein the administration comprises oral administration.

27. The kit of claim 25, wherein the administration comprises intravitreal injection.ny-2734555 423Docket No.: 79275-20026.40 28. The kit of any of claims 21-27, further comprising instructions for administration of an anti-VEGF agent, an Angiopoietin 2 blocking agent, a dual VEGF-Angiopoietin 2 blocking agent, a corticosteroid, or laser therapy to the subject.

29. The method of any of claims 21-28, wherein the compound of Formula (A) is a30. The method of any of claims 21-28, wherein the compound of Formula (B) is a compound of formulany-2734555 424Docket No.: 79275-20026.40ny-2734555 425

Citation Information

Patent Citations

  • Compositions and methods of treating diabetic retinopathy

    US20190255102A1

  • Inhibitors of APOL1 and methods of using same

    US20220106327A1

  • APOL1 inhibitors and methods of use

    WO2022178315A1